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1. Introduction 
1.1. Cardiovascular Diseases 
Cardiovascular diseases (CVDs) had become the United States’ number one cause of 
deaths by the late 1940s (The Framingham Heart Study, 2009) and more people die 
annually from CVDs worldwide than from any other cause (WHO, 2009). CVDs are 
caused by disorders of the heart and blood vessels and include coronary heart disease 
(CHD, heart attacks), raised blood pressure (hypertension), rheumatic heart disease, 
congenital heart disease and heart failure. In 2004, an estimated 7.2 million people 
worldwide died from coronary heart disease and 5.7 million died due to stroke, which 
accounted for the largest percentage of the total of 17.1 million deaths caused by 
CVDs. There are some major risk factors that can be controlled, treated or modified in 
order to avoid CVDs such as tobacco use, physical inactivity, overweight and high 
blood pressure (American Heart Association, 2005). People in low- and middle-
income countries are more exposed to risk factors leading to CVDs and are less 
exposed to prevention efforts than people in high-income countries causing a 
disproportional affection of these countries: 82% of CVD deaths take place in low- and 
middle-income countries (WHO, 2009). 
CHD and other chronic cardiomyopathies lead to segmental loss of cardiac tissue and 
scarring of a large portion of the ventricular wall (Beltrami et al., 1994; Joggerst and 
Hatzopoulos, 2009). Adult hears have a very limited regenerative potential and the loss 
of myocytes and coronary vessels after injury is mostly irreversible. Replacement of 
small areas of dead tissue located within the scarred myocardium has only been 
occasionally seen in humans (Urbanek et al., 2005). Therefore, the only possible cure 
for patients with CVDs is transplantation, which is hampered by a low number of 
suitable donors. 
A relatively new approach against CVDs is stem cell therapy. Stem cell populations 
possess cardiogenic potential and animal models indicate, that the function of 
ventricular muscle after ischaemic injury is improved after transplantation of 
mesenchymal stem cells, bone-marrow-derived haematipoetic stem cells, skeletal 
myoblasts, or embryonic stem cells (Joggerst and Hatzopoulos, 2009). However, the 
generation of new cardiac tissue is low and the benefits for cell therapy are modest 
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(Joggerst and Hatzopoulos, 2009). The identification of an optimal cell type which 
derives from a renewable source and produces sufficient quantities to drive clinically 
relevant levels of cardiomyogenesis (CMG) is a central challenge for cell-based 
therapy (Domian et al., 2009). 
1.2. Murine Heart Development 
The heart is the first functional organ that forms in the developing embryo, starting 
around day E7. It is composed of a variety of different cell types, indicating the 
complexity of its morphology. It consists of diverse muscle and non-muscle cell 
lineages, atrial and ventricular cardiac myocytes, conduction system cells, smooth 
muscle and endothelial cells of the coronary arteries and veins, endocardial cells, 
valvular components and connective tissue (Laugwitz et al., 2008). Heart formation 
therefore needs to be a a precisely coordinated process of cellular differentiation and 
morphogenesis (Akazawa and Komuro, 2005). Cardiogenic mesoderm, the cardiac 
neural crest and the proepicardial organ have been identified as the three major sources 
of heart precursors which give rise to the distinct cardiac compartments (Laugwitz et 
al., 2008). Development of those progenitors is spatially and temporally segregated in 
the developing embryo (Fig. 1). 
The cardiogenic mesoderm itself consits of two different lineages of cardiac 
precursors. It is distinguished between progenitors giving rise to cells of the first heart 
Fig. 1 Murine heart development and origin of heart structures. The cardiogenic mesoderm (red), the cardiac 
neural crest (purple), and the proepicardium (yellow) are the three major progenitors in murine heart development 
and contribute to different heart compartments. Cardiogenic mesoderm cells form the linear heart tube and the 
four chambers of the heart. Cardiac neural crest progenitors engulf the aortic arch arteries after looping occurred 
on day 8.5 and they furthermore differentiate to vascular smooth muscle cells of the outflow tract. The epicardial 
mantle and coronary vasculature origins from cells of the proepicardium. AA, aortic arch; IVS, interventricular 
septum; LA, left atrium; LV, left ventricle; PhA, pharyngeal arches; PLA, primitive left atrium; PRA, primitive 
right atrium; RA, right atrium; RV, right ventricle (Laugwitz et al., 2008). 
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field and the second heart field (Buckingham et al., 2005). The first heart field  
comprises the cardiac crescent, the linear heart tube, parts of the left and right atria and 
the left ventricular region. The outflow tract and the right ventricular region make up 
the second heart field (Buckingham et al., 2005). Highly differentiated cardiomyocytes 
after birth lose their ability to proliferate. They only grow in size to adapt to a demand 
for an increased workload (Akazawa and Komuro, 2005). 
1.3. Stem Cells 
Stem cells are cells with a capacity to self-renew and to generate daughter cells that 
can differentiate into several lineages to form all of the cell types that are found in the 
mature tissue. Self renewal means that a progenitor gives rise to daughter progenitors 
of equivalent developmental potential. Stem cells can either divide symmetrically to 
two identical cells of the same developmental potential to expand the stem-cell 
compartment. They can also generate by asymmetric cell division one cell identical to 
itself and one cell that is distinct. The third option is division to two daughter cells 
with less potential than the stem cell. The distinct cells go through a series of cell 
divisions and differentiative steps, forming intermediates or progenitor cells to finally 
develop to the terminally differentiated cell populations (Smalley and Ashworth, 
2003). Stem cells are classified in regard to the different cell types they are able to give 
rise to. 
Totipotent stem cells have the ability to differentiate to all cell types of the body as 
well as to all cell types that make up the extraembryonic tissue during embryogenesis. 
The only totipotent cells are the zygote and the developing cells after rapid division of 
the zygote until the 16-cell developmental stage. 
Pluripotent stem cells are able to give rise to cells of all three germ layers of the 
embryo. However, they cannot form extraembryonic tissue. 
Multipotent stem cell have the ability to develop into more than one cell type of the 
body and unipotent stem cells are restricted to one cell type to which they differentiate 
(NIH, 2001). 
Stem cells reside in a three-dimensional structure, a so called stem cell niche. These 
stem cell niches consist of a variety of heterologous cells. They must have both 
anatomic and functional dimensions, specifically enabling stem cells to reproduce or 
self-renew (Scadden, 2006). A stem cell niche should consist of extracellular matrix, 
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the stem cells, and signalling cells affecting the stem cells (Lin, 2002). Various 
elements of the local environment regulate the stem cell developmental status by 
providing signals for self-renewal or differentiation (Fig. 2) (Scadden, 2006). Adult or 
somatic stem cells have limited function without the niche, cardiac stem cells cannot 
exist in the absence of supporting cells which anchor the stem cells to the niche and 
modulate growth signals (Urbanek et al., 2006). It is the niche that provides the 
modulation in stem-cell function needed under conditions of physiological challenge 
(Scadden, 2006). Obtaining signals for activation, cell division occurs and cells 
migrate out of the niches to sites of cell replacement where they differentiate and 
aquire the adult phenotype. Niche homeostasis is regulated by division of stem cells 
which preserves the ideal proportion of primitive and committed cells within the organ 
(Fuchs et al., 2004). 
1.4. Embryonic Stem Cells 
The fusion of sperm and egg gamets results in the formation of a zygote and initiates a 
series of cell divisions. On days 3 – 4, a blastocyst develops which is characterized by 
the presence of a blastocyst cavity, an inner and outer cell mass (O'Connor and Crystal, 
2006). By the time of implantation on days 4 – 5, three distinct cell types are apparent 
in the mouse blastocyst which give rise to separate cell lineages in later development. 
The inner cell mass develops to the Epiblast (primitive ectoderm) which gives rise to 
the entire fetus as well as extraembryonic mesoderm, and to the Hypoblast (primitive 
endoderm) which forms the extraembryonic endoderm layers of the visceral and 
parietal yolk sacs. The outer cell mass or trophectoderm gives rise to all the 
Fig. 2 Different elements of niche influence on stem cell state. The local environment of stem cells provides signals 
to adapt stem cells under conditions of physiologic challenge. Humoral, structural, metabolic, physical, neuronal and 
paracrine signals influence the differentiation mode of the stem cells (Scadden, 2006). 
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trophoblast cell types that make up the majority of the fetal part of the placenta  
(Chazaud et al., 2006). 
Embryonic stem cells (ESCs) are pluripotent cells that are isolated from the inner cell 
mass of embryos at the blastocyst stage (Fig. 3). The second broad category of stem 
cells is derived from various fetal and post-natal organs, the so called somatic stem 
cells. Those stem cells generally have been thought of as tissue specific, able to only 
give rise to progeny cells found in the tissue of their origin (O'Connor and Crystal, 
2006; Wagers and Weissman, 2004).  
The advantages of ESCs compared to somatic stem cells are, that they are easier to 
identify, isolate and to maintain as an established stem cell line (Boiani and Scholer, 
2005). As pluripotent cells, they have the ability to divide symmetrically in culture and 
give rise to daughter cells that are exact copies of the stem cells from which they were 
derived. Therefore, cells can be expanded in culture before differentiation to all cell 
types of the embryo can be initiated. They undergo differentiation steps resembling the 
in vivo developmental programs and are therefore a good model system to study 
differentiation and lineage commitment. 
Fig. 3 Derivation of embryonic and somatic stem cells. Embryonic stem cells are isolated of inner cell mass cells 
in the blastocyst stage of embryonic development. They can be cultured, kept in self-renewal mode and upon 
differentiation signals, they have the ability to form all cell types of the three germ layers. Somatic stem cells are 
present in many fetal and post-natal tissues. Somatic stem cells are also capable of self-renewal and, with 
appropriate signals, differentiate into various cell types of the organ from which they are derived (O'Connor and 
Crystal, 2006). 
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1.5. Embryoid Bodies 
ESCs can be maintained in a pluripotent self renewal state when they are grown on 
mitotically inactivated, Leukemia Inhibitory Factor (LIF) secreting fibroblast feeder 
cells. Transfer from feeder cells to gelled plates results in the differentiation of these 
cells. The formation of embryoid bodies (EBs) is a very well established and 
reproducable method for mimicking the early in vivo development of the embryo. 
Embryoid bodies are ESCs which form aggregates without any contact to artificial 
material. The first cells that occur are primitive endoderm cells which form a single 
layer sourrounding the inner cell mass, which becomes the primitive ectoderm (Ikeda 
et al., 1999). Therefore differentiating EBs resemble a murine blastocyst in many 
aspects. At day 4.5 EBs are transferred to gelled plates. Attachment to the matrix 
induces the differentiation of primitive endoderm to parietal endoderm and migration 
away from the center of the EB which mimics the migration of parietal endoderm 
along the inner surface of the trophectoderm in implanting blastocysts (Fig. 4) (Bader 
et al., 2001).  
Further differentiation of EBs results in the formation of cells of all three germ layers 
such as cardiomyocytes, hematopoetic progenitors, yolk sac, skeletal myocytes, 
smooth muscle cells, adipocytes, hepatocytes, chondrocytes, endothelial cells, 
melanocytes, neurons, glia, pancreatic islet cells, and primitive endoderm (Itskovitz-
Eldor et al., 2000; Keller, 1995). 
Fig. 4 Embryoid body development mimics early steps of embryogenesis. Comparison of an in vitro development 
of embryoid bodies on day 7 with the in vivo embryogenesis at the egg cylinder stage (Weitzer, 2006). 
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1.6. Maintaining Stem Cell Pluripotency 
Naive pluripotency of early epiblast and embryonic stem cells is maintained by the 
activity of three transcriptional organizers, octamer binding transcription factor 4 
(Oct4), sex determining region Y box 2 (Sox2), and Nanog. They are described as the 
trinity of nuclear regulators, building a self-assembling and self-sustaining network to 
govern pluripotency in vivo and in vitro by continuous suppression of lineage specific 
factors (Chambers and Smith, 2004; Niwa, 2007). Oct4 and Sox2 also direct the 
expression of fibroblast growth factor 4 (FGF4), a differentiation inducing protein. 
FGF4 activates the mitogen activated protein kinase (MAPK) pathway (Kunath et al., 
2007) which destabilisizes the self-renewal state of stem cells and promotes lineage 
specification by rendering the cells responsive to further inductive signals (Silva and 
Smith, 2008) (Fig. 5). This effect of the two stemness factors might appear 
controversial. However, in development epiblast cells are meant to differentiate. 
Therefore, the system is made to eliminate ESCs. To keep ESCs in an naive, 
undifferentiated state requires overcoming normal developmental progression. 
Conventionally, extrinsic stimulation of Signal transducer and activator of 
transcription 3 (Stat3) by cytokine leukemia inhibitory factor (LIF) maintains murine 
ESCs. Furthermore, either bone morphogenetic protein (BMP) or serum have to be 
added to induce inhibitors of differentiation (ID) proteins (Ying et al., 2003).  
FGF4 acts by activation of the mitogen activated protein kinase (MAPK) pathway. 
FGF4 mutants have minimal requirement for LIF and serum/BMP, however neither 
LIF, nor serum/BMP block the activation of extracellular signal regulated kinase 
(ERK). Stat3 and ID proteins may directly antoagonize effectors downstream of ERK 
(Silva and Smith, 2008; Ying et al., 2008).  
Therefore, LIF/Stat3 and BMP/Smad/ID siganlling do not instruct self-renewal but 
shield the pluripotent state from induced MAPK signalling (Ying et al., 2008). LIF 
also promotes ESC growth and viability (Silva and Smith, 2008).  
 Fig. 5 Maintaining pluripotency. Sox2 and 
Oct4 activate expression of FGF4 which 
activates the MAPK pathway, resulting in 
lineage commitment and differentiation (Silva 
and Smith, 2008). 
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Maintaining pluripotency does not seem to be predetermined in epigenetics, epigenetic 
patterns are rather changed due to the differentiation controlling stimuli (Silva and 
Smith, 2008). 
Elimination of differentiation-inducing FGF4 signalling results in a general reduction 
of differentiation and self renewal is enabled (Ying et al., 2008). However, in the 
presence of a very potent MEK inhibitor, PD0325901, ESCs degenerated. Culture with 
a combination of two inhibitors, the MEK inhibitor PD0325901 and the glycogen 
synthase kinase (GSK3) inhibitor CHIR99021, gives rise to ESCs with clonal 
propagation, they are able to give somatic chimears and germline transmission. 
Shielding from ERK seems to enable self-renewal and this is stabilized by the 
inhibition of GSK3 (Ying et al., 2008). The two inhibitors liberate ESCs from 
requirements for exogenous factors without compromise to developmental potency 
(Ying et al., 2008). Still, the optimal condition of growing ESCs is always with LIF, 
culture of LIF + the two inhibitors promotes self renewal better than either inhibitor in 
combination with LIF or the two inhibitors alone. And those combinations work better 
than LIF + serum/BMP. It was also possible to isolate ESC lines from any mouse 
strain and from rats with the two inhibitors and LIF (Smith, unpublished data).  
Very recently, two other transcription factors, Kruppel like factors 2 and 4 (Klf2 and 
Klf4) were identified as being important in maintaining pluripotency (Guo et al., 2009; 
Smith, unpublished data). Klf2 and klf4 genes are predominantly downregulated during 
differentiation of ESCs into Epiblast stem cells (EpiSCs), they are expressed in ESCs 
but not in EpiSCs. EpiSCs are derived from post-implantation epithelialized epiblasts. 
They are in a similar ground state as ES cells with an autonomous capacity for survival 
and replication (Nichols et al., 2009). They are capable of multilineage differentiation 
in vitro, express the core pluripotency genes Oct4, Sox2, and Nanog but are unable to 
repopulate a host blastocyst (Brons et al., 2007; Guo et al., 2009; Tesar et al., 2007). 
Introduction of either klf2 or klf4 genes into the genome of EpiSCs followed by culture 
together with LIF and the two inhibitors resulted in the interconversion of EpiSCs into 
ESCs, the naive ground state was regenerated (Guo et al., 2009; Smith, unpublished 
data). 
9 
 
1.7. Cardiac Progenitor Cells  
Multicellular organisms require the existence and precise control of stem cells that 
maintain tissue homeostasis (Boiani and Scholer, 2005). Slowly dividing stem cells 
give rise to proliferating, lineage restricted progenitor cells which develop to 
terminally differentiated cells replacing aged or injured cells of the various tissues 
(Flickinger, 1999; Kajstura et al., 2008; Quesenberry et al., 2005). Although culture 
and differentiation techniques of ESCs have improved dramatically and ESCs are able 
to differentiate into cardiomyocytes (CMCs) in vitro, the efficiency of this process is 
very low and it remains challenging to obtain cardiomyocyte-enriched cultures (Smits 
et al., 2009).  
Recent results suggest that multipotent, cardiac stem cells (CSCs) exist in the heart and 
consantly give rise to a hierarchy of downstream cellular intermediates and myocyte 
progeny (Laugwitz et al., 2008). They have been identified in the adult heart and reside 
in cardiac niches, which contain CSCs and lineage-committed cells. Connexin and 
cadherins form gap and adherens junctions and connect CSCs to supporting cells such 
as myocytes and fibroblasts (Urbanek et al., 2006). Different groups already succeeded 
in the isolation of somatic stem cells of the heart (Beltrami et al., 2003; Oh et al., 2003; 
Oyama et al., 2007; Pfister et al., 2005). Laugwitz et al. (2008) identified a master 
heart progenitor cell type that ultimatively gives rise to the heart’s three major cell 
types: cardiac muscle, smooth muscle and endothelium. Recent results suggest that a 
defective CSC compartment is a common denominator of heart failure of different 
etiologies (Kajstura et al., 2008). Therefore gaining knowledge about the progenitor 
identity and pathways influencing their differentiation is essential to gain better 
insights into CMG and for regenerative cardiovascular medicine. For this purpose, it is 
important to generate an in vitro model that can achieve differentiation of a 
homogenous population of cardiomyocytes to a reproducible degree (Smits et al., 
2009). Wiedner and Weber (Wiedner, 2008) suceeded in the isolation of stable murine 
cardiovascular progenitor cell (CVPC) lines. CVPCs express the stemness factors 
Oct4, Nanog, and Sox2 in comparable amounts to ESCs as well as cardiac 
transcription factors such as nkx2.5 and myocyte enhancer factor 2C (mef2c) already in 
the undifferentiated state. The cells seem to be somewhere downstream of ESCs, they 
have a predisposition to the cardiac lineage but still have stem cell character. Similar 
cells, expressing stem cell specific genes such as c-kit as well as the cardiac genes 
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nkx2.5, mef2c and GATA binding protein 4 (gata4), were found and isolated from the 
human heart (Smits et al., 2009). 
1.8. Cardiac Transcription Factors 
Cardiac transcription factors are essential gene activators that are expressed in the 
developing heart tissues. The production of structural or regulatory proteins 
characteristic for CMG is regulated by the expression of cardiac-specific genes. They 
therefore have an influence on processes that impact the morphogenesis of the 
developing heart (Bruneau, 2002). Different studies have identified a core group of 
transcription factors that are required for cardiac development, including members of 
the NK class of homeodomain proteins, GATA zinc-finger transcription factors, the 
MADS domain transcription factor Mef2C, Forkhead transcription factors as well as 
the Hand class of basic helix-loop-helix factors (Black, 2007). Nkx2.5 is a critical 
transcription factor in the first and second heart field lineages, Isl1, along with Foxh1 
and GATA factors is the key transcriptional regulator of the second heart progenitor 
field (Laugwitz et al., 2008). Mef2C plays an essential role in the transcriptional 
program for second heart field development whereas it is only weakly expressed in 
first heart field precursors and its derivatives (Black, 2007). The GATA family of zinc 
finger-containing transcription factors appears to be potentially critical in regard to 
progressive differentiation of precardiac cells (Bruneau, 2002).  
The function of transcription factors largely depends on the target genes they regulate, 
therefore identification of such genes is essential to understand the molecular 
mechanisms in cardiac development (Nakashima et al., 2009). Early cardiac marker 
genes are nkx2.5, T-box 5 (tbx5), gata4 and mesoderm posterior 1 (mesp1). Late 
cardiac markers are myosin heavy chain 6 and 7 (myh6 and myh7), myosin light chain 
2 and 2v (mlc2a and mlc2v) (Kwon et al., 2007).  
 
1.8.1. Nkx2.5 
Genetic explorations for cardiac development have started only about a decade ago. 
The first crucial step in studying transcription factors in heart development was the 
discovery of the Drosophila melanogaster gene tinman. It encodes a NK-class 
homeodomain-containing transcription factor which is required for development of 
cardial and visceral lineages (Azpiazu and Frasch, 1993; Bodmer, 1993). Homologues 
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to tinman, the NK homeobox genes, were found in vertebrates. Nkx2.5 is the fifth 
vertebrate gene identified in the NK-2 homeobox gene family (Lints, 1993). 
Nkx2.5 (also called Csx) consists of a N-terminal TN domain, a homeodomain which 
is required for DNA binding, protein interaction, and dimerisation, and a NK-2 
specific domain located C-terminal to the homeodomain (Fig. 6) (Harvey, 1996).  
Nkx2.5 is a myocardial regulatory protein in both heart fields (Biben and Harvey, 
1997) and plays a key role for cardiac transcription in the intricate program of heart 
development (Bruneau, 2002). In mice, nkx2.5 expression begins in the cardiogenic 
mesoderm at embryonic day 7.5 and it is expressed throughout the course of 
development in the heart primordium, as well as in CMCs (Lints et al., 1993). Its 
expression pattern is ubiquitously in the heart tube (Christoffels et al., 2000). Its role in 
cardiac differentiateion is crucial for the normal growth of the embryonic myocardium. 
This becomes apparent in the poorly developed myocardium of mice lacking nkx2.5 
and in the inability to form the primitive cardiac structures beyond the earliest stages 
of heart looping (Lyons et al., 1995; Tanaka et al., 1999). During the late stage of 
cardiogenesis, nkx2.5 plays an important role in lineage specification and maturation 
of ventricular cardiomyocytes (Akazawa and Komuro, 2005).  
Posttranslational modifications, acting either positively or negatively, are likely to 
account for an important component of the regulation of cardiac transcription factors 
(Bruneau, 2002). Nkx2.5 has at least five phosphorylation sites. It was found that 
cytoplasmic Nkx2.5 is unphosphorylated. In contrast, the nuclear Nkx2.5 is 
Fig. 6 Domains oft the Nkx2.5 protein. Nkx2.5 consists of 318 amino acids and is composed of three domains, 
the TN domain (dark grey), the homeodomain (black) and the NK-2 domain (light grey) (Akazawa and Komuro, 
2005). 
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phosphorylated. Casein kinase II (CKII) was identified to phosphorylate serine within 
the Nkx2.5 homeodomain, increasing DNA binding (Kasahara and Izumo, 1999). 
Nkx2.5 physically interacts with other transcription factors such as GATA4, they 
synergistically activate transcription via unmasking the activation domain of DNA-
bound Nkx2.5 as well as recruitment of GATA4 by Nkx2.5 into a transcriptional 
complex (Bruneau, 2002; Charron and Nemer, 1999). 
Nkx2.5 regulates the expression of several cardiac-specific genes, gene expression of 
mlc2v, atrial natriuretic peptide (anp), cardiac ankyrin repeat protein (carp), mef2C, 
eHAND/HAND1, iroquois subclass of homeobox 4 (irx4) and hop-sterila (hop) was 
reduced in nkx2.5 deficient embryos (Biben and Harvey, 1997; Bruneau, 2002; Lyons 
et al., 1995; Tanaka et al., 1999). Working with ESC lines expressing nkx2.5 at 
different levels allowed Nakashima et al. (2009) to identify r-spondin 3 (rspo3) and 
transforming growth factor  beta receptor 3 (tgfbr3) as target genes for nkx2.5. Rspo3 
is one of the ligands for Frizzled homolog 8 (Fzd8) and Low-density lipoprotein 
receptor-related protein 6 (LRP6) and activates the canonical Wnt pathway (Nam et 
al., 2006). Furthermore, Nkx2.5 modulates transforming growth factor beta (TGF-β) 
signalling by enhancing the expression of tgfbr3, which is a TGFβ co-receptor and a 
critical gene for cardiogenesis (Nakashima et al., 2009). Furthermore, β-catenin and 
GATA4 were found to contain Nkx2.5 binding sites in their promoter regions and it 
was detected, that physical interaction between those sequences and Nkx2.5 occurs 
(Riazi et al., 2009). 
1.8.2. Isl1 
Isl1 is the key transcriptional regulator of the second heart field lineage during 
embryogenesis. Its expression is required for survival, proliferation and migration of 
second heart field progenitor cells. Mutation of Isl1 results in a severe cardiac 
phenotype in the second heart field. It is expressed in cells that colonize the outflow 
tract, right ventricle, part of the atria and the inner curvature of the left ventricle (Cai et 
al., 2003) and its transcription is turned off as the precursor cells differentiate 
(Laugwitz et al., 2008). 
1.9. Desmin 
Murine Desmin is a 53 kDa protein which is a member of the type III intermediate 
filament (IF) group. Desmin IFs occur exclusivly in muscle and endothelial cells. It is 
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the first muscle specific structural protein and is one of the more persistent in several 
differentiation conditions (Costa et al., 2004). It has two conserved central rod 
domains (H1 and H2), four linker domains and two globular end domains. The central 
rod domains are responsible for the polymerization by lateral association (Herrmann 
and Aebi, 2000). Desmin occurs at the periphery of the Z disk and may act to keep 
adjacent myofibrils in lateral alignment. Phosphorylation of Desmin regulates the 
polymerisation of IFs (Huang et al., 2002).  
Constitutive expression and increased synthesis during mesoderm formation of 
Desmin cause an up-regulation of the cardiac marker gene nkx2.5. At the same time 
this accelerates early cardiomyogenesis and the cells differentiate into synchronously 
beating cardiomyocytes. The desmin null mutants showed the opposite phenotype, 
fewer contracting heart cells could be detected when differentiated in EBs (Hofner et 
al., 2007). The amino-terminal domain of Desmin is important for its function in heart 
muscle cell development, its deletion decreases in vitro cardiomyogenesis and 
downregulates nkx2.5 expression (Hollrigl et al., 2007). 
1.10. Wnt Signalling 
Wnt proteins are a large family of secreted signalling molecules that regulate crucial 
aspects of development (Cohen et al., 2008). They are glycoproteins that bind to the 
seven-transmembrane-spanning receptors frizzled, triggering a signalling cascade 
which results in altered target gene expression (Fig. 7). In the absence of Wnt, the level 
of free intracellular β-catenin, the transcriptional mediator of Wnt, is minimized by its 
phosphorylation by glycogen synthase kinase 3β (GSK3β). Free cytoplasmic β-catenin 
is recruited to a “destruction complex” containing APC, Axin, and GSK3β. 
Phosphorylation of β-catenin results in its degradation by the proteasome (Fodde et al., 
2001; Hlsken and Behrens, 2000). Binding of Wnt to frizzled activates the receptor 
leading to the phosphorylation of Dishevelled, which in turn inhibits GSK3β. 
Consequentely, β-catenin cannot be phosphorylated, and in its unphosphorylated state 
it translocates to the nucleus where it acts as a transcriptional co-activator that interacts 
with T cell factor and lymphoid enhancer factor (TCF/LEF) transcription factors to 
activate Wnt targets (Bejsovec, 2005). Wnt signalling has a crucial role in controlling 
proliferation and differentiation. It is the key pathway in the regenerative process in 
many tissures, including the heart (Cohen et al., 2008). In flies, wingless, the founding 
member of the canonical Wnt family, is required for cardiac lineage determination  
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(Wu et al., 1995). Overexpression of canonical Wnts in dorsal and anterior mesoderm  
of frogs and chicks inhibits CMC commitment or differentiation. In the cardiac 
crescent, Wnt signalling downregulates the expression of early cardiac genes nkx2.5 
and gata4 (Marvin et al., 2001; Schneider and Mercola, 2001). Decrease in the 
transcriptional activation potential of β-catenin in zebrafish caused hyperproliferation 
of CMCs, indicating that β-catenin negatively regulates CMG (Rottbauer et al., 2002). 
In mammals, activation of β-catenin resulted in the expansion of isl1 expressing CSCs, 
and in early developmental stages in mouse embryos, β-catenin directly regulates isl1 
expression, suggesting an important role for development of the second heart field 
(Cohen et al., 2007; Lin et al., 2007). Inhibiting canonical Wnt signalling with 
Dickopff1 (Dkk1) in embryoid bodies (EBs) between day 4 and 6 resulted in a 
complete absence of beating EBs, implicating that canonical Wnt is required for CMC 
formation in the EB system. In addition to those findings, expression levels of nkx2.5 
and tbx5 were upregulated by exposure to Wnt3a (Kwon et al., 2007). β-catenin 
expression itself was repressed in cardiac myocytes which is mediated by nkx2.5 
(Riazi et al., 2009). Taken together these data, Wnt signalling seems to have a biphasic 
Fig. 7 The canonical Wnt pathway. In the ansecne of Wnt, β-catenin is phosphorylated by GSK3β in complex with 
APC and Axin. Binding of Wnt to its receptor frizzled results in the phosphorylation of Dishevelled (Dsh) which 
indirectly inhibits GSK3β kinase activity. β-catenin is free in the cytoplam and can translocate to the nucleus, 
activating gene expression of TCF/LEF sites controlled genes (Weiss, 2009). 
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role where β-catenin is necessary at earlier stages of CMG and has an inhibitory effect 
at later stages of heart development (Lin et al., 2007; Riazi et al., 2009). 
1.11. SPARC 
Secreted protein acidic and rich in cystein (SPARC), also termed BMP-40 or 
osteonectin, is a 43 kDa matricellular glycoprotein which is produced by several cell 
types, in especially high amounts by the parietal endoderm. SPARC consists of three 
domains, a N-terminal acidic region, a cystein rich follastatin-like domain, and an 
extracellular Ca2+ domain (Fig. 8) (Brekken and Sage, 2000). It is expressed during 
development and in the fetal heart, however not in the adult heart. Its expression is 
limited to areas with high rates of turnover as well as repair and tissue remodelling 
(Sage et al., 1989). Very high expression was detected under condition of stress, in 
response to endotoxin stimulation, heat shock, cellular aging and wound repair 
(Brekken and Sage, 2000). SPARC was detected extracellularily as well as 
intracellularily in the nucleus and assoziated with the nuclear matrix in some cell types 
(Gooden et al., 1999). It was furthermore detected as a secretion product. Extracellular 
SPARC binds to growth factors, cytokines and components of the extracellular matrix 
(ECM), which results in remodelling and explains the role of SPARC in development 
and wound healing (Brekken and Sage, 2000).  
Adenoviral overexpression of SPARC in wild type mice improved the collagen 
maturation and prevented cardiac dilation and dysfunction after myocardial infarction 
and therefore indicated that the local production of SPARC is essential for 
Fig. 8 Structure of SPARC (Secreted Protein Acidic and Rich in Cystein). SPARC consists of three domains, the 
N-terminal, acidic domain, the follastatin-like, and the extracellular Ca2+-binding C-terminal domain (Brekken 
and Sage, 2000). 
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maintainance of the integrity of cardiac ECM after myocardial infarction (Schellings et 
al., 2009).  
SPARC was found to modulate the kinase activity of Integrin-linked-kinase 1 (ILK1) 
by binding to the transmembrane protein integrin-β1 (Barker et al., 2005; Weaver et 
al., 2008). During adipogenesis, SPARC induced the accumulation and nuclear 
translocation of β-catenin and therefore its activity as a transcriptional activator, which 
resulted in an inhibition of adipogenic transcription factors and adipogenesis (Nie and 
Sage, 2009). Therefore, activation of ILK by SPARC might influence the activity of 
GSK3, resulting in an alteration of the level of free β-catenin transcription factor in the 
nucleus (Fig. 9).  
In human dental pulp cells, SPARC was found to act via the G-protein coupled 
receptor integrin αvβ3, which regulates extracellular signal regulated kinase (ERK) 
and consequently induced dental pulp cell migration (Pavasant and Yongchaitrakul, 
2008). 
In respect of cardiomyogenesis, recombinant SPARC was found to enhance early 
cardiomyocyte formation in EBs when added on days 7 – 10. Upregulation of nkx2.5 
was further detected upon SPARC addition (Stary et al., 2005). Histochemical analysis 
Fig. 9 Possible transduction pathway of SPARC signalling. SPARC binds to integrin β1, activating ILK1. ILK1 
might influence the phosphorylation status of GSK3, altering the concentration of free cytoplasmatic β-catenin 
which translocates to the nucleus and activates targe gene expression (Weiss, 2009). 
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revealed, that addition of SPARC to EBs gave rise to an expansion of the peripheral 
endoderm, with thicker layers of ECM material (Hrabchak et al., 2008). 
Here, we wanted to investigate the influence of the two proteins Desmin and SPARC 
on cardiomyogenesis. Our aim was to determine the mechanism through which 
Desmin promotes cardiomyogenesis by establishing a link between Desmin and the 
early cardiac transcription factor Nkx2.5. We furthermore tried to detect the effect of 
SPARC on cardiomyocyte formation in isolated cardiovascular progenitor cells, whose 
differentiation potential is restricted to the cardiac lineage. The determination of 
signalling pathways through which SPARC acts and the detection of effector genes 
altered in their expression upon SPARC addition would help elucidating the 
mechanism of its influence. 
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2. Abbreviations 
 
ANP Atrial Natriuretic Peptide 
APC Adenomatosis Polyposis Coli 
BMP Bone Morphogenetic Protein 
CARP Cardiac Ankyrin Repeat Protein 
CB Cardiac Body 
cDNA Complementary Deoxyribonucleic Acid 
CHD Coronary Heart Disease 
ChIP Chromatin Immunoprecipitation 
c-kit Kit Oncogene 
CK Casein Kinase 
CMC Cardiomyocyte 
CMG Cardiomyogenesis 
CSC Cardiac Stem Cell 
cTNT Cardiac Troponin T 
CVD Cardiovascular Disease 
CVPC Cardiovascular Progenitor Cell 
Cx43 Connexin 43 
DAPI 4'-6-Diamidino-2-phenylindole 
Dkk-1 Dickkopf-1 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO Dimethylsulfoxid 
dNTP Deoxy Nucleotide Triphosphate 
DTT Dithiothreitol 
Dsh Dishevelled 
EB Embryoid Body 
EDTA Ethylenediaminetetraacetic Acid 
EGFP Enhanced Green Fluorescence Protein 
EpiSC Epiblast Stem Cell 
ERK Mitogen Activated Protein Kinase 1 
ESC Embryonic Stem Cell 
ETC Endothelium-like Cell 
FACS Fluorescence Activated Cell Sorting 
FGF Fibroblast Growth Factor 
FOX Forkhead Box 
Fzd Frizzled 
19 
 
GATA4 GATA-binding Protein 4 
GAPDH Glyceraldehyde-3-Phosphate Dehydrogenase 
GFP Green Fluorescence Protein 
GSK3 Glycogen Synthase Kinase 3 
HDAC Histone Deacetylase 
ID Inhibitor of Differentiation 
IF Intermediate Filament 
ILK Integrin Linked Kinase 
IRX4 Iroquois Subclass of Homeobox 4 
Isl 1 Islet 1 
Klf Kruppel-like Factor 
LIF Leukemia Inhibitory Factor 
LRP6 Low Density Lipoprotein Receptor Related Protein 6 
MAPK Mitogen Activated Protein Kinase 
MEF2C Myocyte Enhancer Factor 2C 
Mesp1 Mesoderm Posterior 1 
MHCα Myosin Heavy Chain α 
MLC Myosin Light Chain 
mRNA Messenger Ribonucleic Acid 
MYH Myosin Heavy Chain 
Nkx2.5 NK2 Transcription Factor Related, locus 5 
Oct3/4 Octamer-binding Transcription Factor 3/4 
pCMC Primary Cardiomyocytes 
PCR Polymerase Chain Reaction 
Rspo3 R-spondin 3 
SC Stem Cell 
siRNA Short Interfering Ribonucleic Acid 
SMC Smooth Muscle Cell 
Sox2 SRY – related Box 2 
SPARC Secreted Protein Acidic and Rich in Cystein 
Stat3 Signal Tranducer and Activator of Transcription 3 
TBX T Box Family 
TCF T-cell specific Transcription Factor 
TGF-β Transforming Growth Factor β 
TGFBR3 Transforming Growth Factor β Receptor 3 
Wnt Wingless-related MMTV Integration Site 
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3. Results 
3.1. Influence of Desmin on Cardiomyogenesis 
3.1.1. Interaction of Desmin with nkx2.5 Promoter DNA 
Desmin overexpression in embryonic stem cells (ESCs) results in accelerated 
cardiomyogenesis and in the development of large, highly interconnected, and 
synchronously beating clusters of cardiomyocytes (Hofner et al., 2007). A marker for 
early heart development is Nkx2.5 (Ching-Ling, L. et at, 1999). Hofner et al. (2007) 
showed that constitutive expression of desmin led to an increase in nkx2.5 expression. 
However, the mechanism how this activation works is not known yet. The aim of this 
experiment was to establish a link between those two proteins. Desmin might directly 
influence nkx2.5 expression and we wanted to analyse whether there is a physical 
interaction between the protein Desmin and the nkx2.5 promoter region. Furthermore, 
the time frame in which Desmin binds to the DNA region shall be determined in cells 
of different genotypes. 
Physical DNA-Protein interactions are detected with Chromatin-Immunoprecipitation 
(ChIP). The experiment was performed with embryoid bodies of different desmin allels 
and in different developmental stages, with undifferentiated and differentiated 
cardiovascular progenitor cells, and with primary cardiomyocytes. 
3.1.1.1. Interaction in Embryonic Stem Cells 
Embryoid bodies were made from AB2.2 wild type ESCs and from DC6 ESCs (des+/+ 
desect), which overexpress Desmin. Furthermore 1B44 ESCs (des∆1-48/∆1-48), whose N-
terminus of the desmin gene is deleted, and des-/- ESCs, which have the whole desmin 
gene deleted, were tested. Samples for the ChIP experiment of all genotypes were 
taken from days 5 – 9, 1B44 and des-/- EBs were also tested on day 10. ChIP was 
performed with antibodies directed against Desmin and PCRs were made with primers 
recognising sequences directly upstream the nkx2.5 start codon (Fig. 10, P1). PCR 
products were loaded to a 1.5% agarose gel and the samples before (IN) and after (IP) 
immunoprecipitation were compared. 
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The wild type EBs ChIP PCR shows, that in the original input samples (IN) there is a 
clear DNA band at all days. This means that the samples contained nkx2.5 promoter 
DNA and therefore the original material had the necessary basic conditions for the 
immunoprecipitation. At day 5 after immunoprecipitationprecipitation (IP), no PCR 
band could be detected indicating that no Desmin protein was bound to the nkx2.5 
promoter DNA at very early developmental stages in wild type embryoid bodies. At 
day 6, there is a band visible, which suggests a physical interaction of Desmin and 
nkx2.5 promoter DNA at this time point. The same result could be seen at day 8. First 
beating activity in wt EBs was observed on days 6.5 – 7.5. A peculiar observation is, 
that on day 7 Desmin – nkx2.5 promoter interaction could not be detected. This is in 
agreement with unpublished data by Sonja Gawlas. At day 9, no co-
immunoprecipitation of Desmin and nkx2.5 promoter DNA could be overserved (Fig. 
11). 
In the DC6 (des+/+ desect) EBs Desmin – nkx2.5 interaction could be detected on day 5, 
day 6 and day 7, which was one day earlier compared to wt EBs. Desmin was 
overexpressed in the DC6 cells and this overexpression resulted in the earlier binding 
of Desmin to the cardiac development marker gene nkx2.5. As in the wt cells, two days 
after the first detected interaction the signal disappeared (Fig. 11) and one day before 
first beating cardiomyocytes were observed, which was on day 6 in DC6 EBs, the 
interaction occured. This suggests, that the developmental progression is identical in 
the two genotypes, but time-shifted. 
In 1B44 (des∆1-48/ ∆1-48) EBs no binding of Desmin to the nkx2.5 promoter DNA could 
be detected at any tested day (Fig. 11). The missing amino-terminus is thought to be 
the DNA-binding component of the protein and these results provide another hint that 
this might be true. Des-/- EBs served as a negative control, no Desmin was produced 
and no PCR band appeared after immunoprecipitation (Fig. 11). 
Fig. 10 Nkx2.5 Promoter Region. Different primer pairs in the nkx2.5 upstream region recognising sequences in the 
nkx2.5 promoter, P1 and P2, and in the nkx2.5 enhancer sequence, D1 and D2 (Ching-Ling, et al., 1999). 
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3.1.1.2. Interaction in Cardiovascular Progenitor Cells and primary 
Cardiomyocytes 
The same ChIP experiment was performed with A5 cardiovascular progenitor cells 
(CVPCs) and primary cardiomyocytes (pCMCs). Samples of A5 cells were taken in an 
undifferentiated state as well as on day 17 of cardiac bodies development, where 100% 
of all cardiac bodies contained differentiated cardiomyocytes. pCMCs were isolated 
from new born mice (d 0) and immediately used for ChIP. Undifferentiated A5 cells 
did not have Desmin bound to the nkx2.5 promoter region. However in differentiated 
A5 cells, which have already formed beating heart cells in cardiac bodies, a clear 
interaction between Desmin and the nkx2.5 promoter region could be detected. Desmin 
bound to the nkx2.5 promoter region was still detectable in differentiated heart cells as 
seen in the primary cardiomyocytes ChIP PCR (Fig. 12). 
  
Fig. 11 Chromatin Immunoprecipitation (ChIP) of wt, DC6 (des+/+ desect), 1B44 (des∆1-48/∆1-48)and -/- (des-/-) 
embryoid bodies. ChIP was performed of wt, DC6, 1B44 and des-/- embryoid bodies at different 
developmental stages. For the Immunoprecipitation Desmin antibody was used and PCRs with nkx2.5 
promoter primers showed whether Desmin physically binds to the nkx2.5 promoter region at different days of 
development. The input samples (IN) are the PCR results of the whole chromatin before immunoprecipitation 
was performed; the immunoprecipitation samples (IP) reflect the PCR results of the immunoprecipitated DNA 
fragments. The ChIP was done once. The wt and DC6 PCR displays results of three out of seven PCRs. The 
1B44 and -/- PCR was made five times, showing the same result. 
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3.1.2. Influence of Desmin on the nkx2.5 Promoter 
3.1.2.1. Influence of Desmin on the nkx2.5 Promoter in C2C12 Myoblasts 
The previous ChIP experiment showed that Desmin physically binds to the nkx2.5 
promoter. This binding was detected in embryoid bodies derived from wild type and 
DC6 embryonic stem cells, in differentiated A5 CVPCs and in pCMCs. The physical 
binding suggests that Desmin could influence the expression of nkx2.5. 
In this experiment we wanted to investigate in which way Desmin influences the 
expression of nkx2.5. It should be tested whether it has a positive effect and therefore 
activates gene expression or whether it inhibits expression by binding to the promoter 
region.  
For that purpose, we made a Luciferase assay with cells transfected with different 
plasmids. We used a control plasmid containing a luciferase reporter gene without a 
promoter, a vector expressing a luciferase gene regulated by the nkx2.5 promoter (nkx-
luc), and a vector expressing a luciferase reporter gene regulated by the nkx2.5 
promoter and enhancer sequences (nkx-enhancer-luc). To test the effect of Desmin 
overexpression on Luciferase activity, a desmin expressing plasmid was used (Des). 
To downregulate the Desmin level in the cells, we furthermore transfected cells with a 
plasmid containing a sequence for a siRNA targeted against desmin mRNA (Des-
siRNA). As an internal control we used a Renilla plasmid, carrying a Renilla luciferase 
gene, which should be expressed in each cell and therefore reflect the cell count and 
transfection efficiency. A plasmid without any reporter gene (pUC plasmid) was used 
to keep the amount of DNA constant in the different samples. An in vitro expression 
Fig. 12 Chromatin Immunoprecipitation (ChIP) of CVPCs and pCMCs. ChIP was performed of undifferentiated 
A5 CVPCs, differentiated day 17 A5 CBs and pCMCs isolated from day 0 wild type mice. For the 
immunoprecipitation Desmin antibody was used and PCRs with nkx2.5 promoter primers showed whether 
Desmin physically binds to the nkx2.5 promoter region. The input samples (IN) reflect the PCR results of the 
whole chromatin before immunoprecipitation was performed; the immunoprecipitation samples (IP) are the PCR 
results of the immunoprecipitated DNA fragments. For the IPnegative sample, no antibody was used. The ChIP 
was made once, displayed A5 results represent two out of five PCR results, pCMC PCRs were made three times, 
two showed demonstrated results. 
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In a first experiment 1.2 x 105 C2C12 myoblasts were transfected by Calcium 
Phosphate Transfection with a control plasmid, the nkx-luc plasmid and we 
furthermore co-transfected nkx-luc with a plasmid expressing a siRNA directed against 
desmin mRNA. In addition to those vectors, all cells were transfected with the Renilla 
plasmid. Renilla luciferase should be constantly expressed from this plasmid by all 
cells and therefore served as an internal control. 48 hours after transfection, the cells 
were lysed and Luciferase activity was measured. The Luciferase signals were divided 
by the Renilla signals in order to eliminate fluctuations caused by varying cell counts 
or different transfection efficiencies. The cells transfected with the nkx-luc plasmid 
produced Luciferase to a greater extent than the control cells (Fig. 13 A). Thus, it 
could be concluded, that the nkx2.5 promoter is active in C2C12 myoblasts. The co-
transfection with the desmin-siRNA plasmid resulted in a 7 fold reduction of the 
Luciferase signal compared to nkx-luc (Fig. 13 A). 
We then repeated the experiment using the same method and plasmids and saw 
opposite results. The nkx2.5 promoter again is active in the cells as seen on the 
Fig. 13 Effect of desmin knock down on nkx2.5 expression. C2C12 myoblasts were transfected by calcium 
phosphate transfection with a control plasmid, containing a promoterless luciferase gene, with the nkx-luc plasmid 
that expresses a luciferase reporter gene under control of the the nkx2.5 promoter region. The des-siRNA plasmid 
was co-transfected with the nkx-luc vector in order to test the effect of desmin knock down by the desmin siRNA 
on the nkx2.5 promoter activity. All cells were futhermore transfected with a Renilla luciferase expressing 
plasmid, which should be constantly expressed in all transfected cells. 48 hours after transfection, the cells were 
lysed and Luciferase activity was measured. The Luciferase signals were divided by the Renilla signals in order to 
eliminate fluctuations because of different cell counts or different transfection efficiencies. (A) and (B) display the 
results of  two identical experiments.  
A B 
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increase in Luciferase activity in the nkx-luc transfected cells compared to the contol 
cells. However, the desmin siRNA did not cause a decrease in reporter gene 
expression, in contrast it even enhanced the nkx2.5 promoter activity and would 
therefore suggest a negative effect of Desmin on the expression of nkx2.5 (Fig. 13 B). 
However, looking at the Renilla values in both experiments by which the Luciferase 
activities were divided to avoid fluctuations caused by varying cell counts or different 
transfection efficiencies we found that there are high fluctuations in the different 
samples (up to 200 fold) although the same cell count was seeded and the same 
amount of Renilla plasmid was transfected. Futhermore the transfection efficiency was 
very low, when detecting the GFP-positive cells (those cells which have taken up a 
des-siRNA plasmid) under the fluorescence microscope (data not shown). Because of 
these technical problems, a different transfection method, transfection with 
Lipofectamine 2000, was used for the following experiments. 
For transfection with Lipofectamine 2000, the optimal ratio and quantitiy of 
transfection agent and DNA had to be determined. Therefore, C2C12 cells were 
transfected with a GFP expressing plasmid using different Lipofectamine – DNA 
ratios and quantities. An increase of DNA amount from 5 µg to 8 µg per transfection 
also increased the transfection efficiency (Fig. 14). Adding higher Lipofectamine 
concentrations however did not result in a higher amount of transfected cells. No 
difference could be detected using 8 µg DNA with 10 µl Lipfectamine or 8 µg DNA 
with 20 µl Lipofectamine. The DNA-Lipofectamine ratio of 1:1.25 using 8 µg DNA 
with 10 µl Lipofectamine 2000 seemed to be the most efficient for transfection of 
C2C12 myoblasts and was therefore used for further transfection experiments. 
  
The following experiment tested the Lipofectamine transfection method with regard to 
Renilla values. Different cell counts were seeded in duplicates on six well plates and 
Darkfield Images      
Fig. 14 Transfection efficiency of different Lipofectamine 
images of C2C12 myoblasts transfected with a GFP expressing plasmid using 4 µg DNA + 10 µl Lipofectamine (A), 
5 µg DNA + 10 µl Lipofectamine (B), 8 µg DNA + 10 µl Lipofectamine (C), 6 µg DNA + 15 µl Lipo
8 µg DNA + 20 µl Lipofectamine (E).
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fectamine (D), 
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the same Renilla plasmid concentration was added to the cells. The Renilla activity 
was measured 48 hours after transfection. 
 
 
The experiment was made twice and the standard derivation was very low (Fig. 15) 
which favours this transfection method compared to calcium phosphate transfection. 
The Renilla activity depended on the seeded cell count. Interestingly, the lower the cell 
count, the higher the activity (Fig. 15). The cell count was measured when the cells 
were seeded, 24 hours before the transfection and 72 hours before the Luciferase assay. 
One possible way of explaining this fact could be that the cells that were not seeded 
very densely have space to grow and proliferate, are in a better state at the time of 
transfection and are able to express the plasmid more efficiently whereas the 2 x 105 
seeded cells are not in an optimal growing phase and have a lower level of expression. 
1.5 x 105 cells per well were used for the following experiments. 
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Fig. 15 Renilla activity in different cell counts. Different C2C12 cell counts were seeded in duplicates and were 
transfected with the same Renilla plasmid concentration. After 48 hours, Renilla activity was measured. Data are 
means of two experiments. 
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We then used Lipofectamine transfection with the optimised protocol for the next 
experiments. 1.5 x 105 C2C12 myoblasts were transfected with a control plasmid, a 
nkx-luc plasmid, and we furthermore co-transfected nkx-luc with a desmin knock-
down plasmid. siRNA against desmin caused a significant decrease in nkx2.5 promoter 
controlled Luciferase expression (Fig. 16). This suggests, that downregulation of 
Desmin inhibits nkx2.5 expression.  
We then wanted to test the effect of Desmin on the nkx2.5 enhancer region which is 
located further upstream the nkx2.5 promoter. For that purpose, we transfected cells 
with a plasmid carrying a luciferase reporter gene regulated by the nkx2.5 promoter 
and enhancer sequence (nkx-enhancer-luc). We furthermore co-transfected this vector 
with a plasmid expressing a desmin siRNA. The promoter and enhancer sequences are 
active in the cells since Luciferase is produced in the nkx-enhancer-luc transfected 
cells compared to the control cells. However, expression could not be inhibited by co-
transfection of the desmin-siRNA plasmid (Fig. 17).  
pGL3b (control)     +           –                             – 
nkx-luc      –           +                             + 
des-siRNA     –           –                             + 
Fig. 16 Effect of desmin knock down on nkx2.5 expression.. 1.5 x 105 C2C12 myoblast cells were transfected by 
Lipofectamine transfection with a control plasmid, containing a promoterless luciferase gene, with the nkx-luc 
plasmid that expresses a luciferase reporter gene under control of the the nkx2.5 promoter region. The des-siRNA 
plasmid was co-transfected with the nkx-luc vector in order to test the effect of desmin knock down on nkx2.5 
promoter activity. All cells were futhermore transfected with a Renilla luciferase expressing plasmid, which is 
constantly expressed in all transfected cells. 48 hours after transfection, the cells were lysed and Luciferase activity 
was measured. The Luciferase signals were divided by the Renilla signals in order to eliminate fluctuations because 
of different cell counts or different transfection efficiencies. Data are means of two experiments. 
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To test the effect of additional transfected Desmin, another Lipofectamine transfection 
was made with C2C12 myoblasts. Cells were transfected with a control plasmid, the 
nkx-luc plasmid and with a plasmid expressing desmin (Des). All cells were 
furthermore transfected with Renilla. 48 hours after the transfection the cells were 
lysed and the Luciferase signal was measured and evaluated in the same way as the 
other experiments. The co-transfection of the Desmin plasmid caused increased desmin 
expression in the cells which was affirmed by isolating mRNA of transfected cells 
followed by Desmin PCRs (Fig. 18 B). However, this additional Desmin could not 
activate the nkx2.5 promoter. Even less reporter gene was expressed than without the 
co-transfected Desmin plasmid (Fig. 18 A). 
 
 
Control         nkx-enhancer-luc              nkx-enhancer-luc  
                   + des-siRNA 
Fig. 17 Effect of desmin knock down on nkx2.5 expression. 1.5 x 105 C2C12 myoblast cells were transfected by 
Lipofectamine transfection with a control plasmid, containing a promoterless luciferase gene, with the nkx-
enhancer-luc plasmid that expresses a luciferase reporter gene under control of the the nkx2.5 promoter and 
enhancer region. The des-siRNA plasmid was co-transfected with the nkx-enhancer-luc vector in order to test the 
effect of desmin knock down by the desmin siRNA on the nkx2.5 promoter and enhancer activity. All cells were 
futhermore transfected with a Renilla luciferase expressing plasmid, which is constantly expressed in all transfected 
cells. 48 hours after transfection, the cells were lysed and Luciferase activity was measured. The Luciferase signals 
were divided by the Renilla signals in order to eliminate fluctuations because of different cell counts or different 
transfection efficiencies. The experiment was made once. 
pGL3b (control)  +        –                             –  
nkx-luc-enhancer  –        +                             + 
des-siRNA  –        –                             + 
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3.1.2.2. Influence of Desmin on the nkx2.5 Promoter in primary Cardiomyocytes 
Heart cells of five days old mice were isolated and transfected with a control plasmid, 
the nkx-luc plasmid and we furthermore co-transfected nkx-luc with a plasmid 
expressing a siRNA directed against desmin mRNA. 48 hours after transfection, the 
cells were lysed and Luciferase activity was measured. We found that the co-
transfection with the knock down plasmid did not change the Luciferase activity in 
pCMCs (Fig. 19). In earlier ChIP experiments it was detected, that Desmin is bound to 
the nkx2.5 promoter in day 0 pCMCs. In day 5 pCMCs, Desmin seems to have no 
effect on the expression of nkx2.5. 
Fig. 18 Effect of ectopic Desmin expression on the nkx2.5 promoter. 1.5 x 105 C2C12 myoblasts were transfected 
with the nkx-luc plasmid that contains the nkx2.5 promoter region with a luciferase reporter gene. The Desmin 
plasmid contains the desmin cDNA and therefore produces a desmin mRNA that can be translated to the protein.
(A) 48 hours after transfection, the cells were lysed and Luciferase activity was measured. The Luciferase signals 
were divided by the Renilla signals in order to eliminate fluctuations because of different cell counts or different 
transfection efficiencies. The experiment was made once. (B) 48 hours after transfection, RNA was isolated, 
transcribed into cDNA and a PCR with primers for desmin was made to confirm the overexpression of desmin in 
the trasfected cells. A GAPDH PCR was made to ensure that the same quantities of cDNA was used in the PCR. 
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pGL3b (control)           +                 –                              –  
nkx-luc            –                 +                              + 
Desmin            –                 –                              + 
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Fig. 19 Effect of desmin knock down on nkx2.5 expression in primary cardiomyocytes. Primary cardiomyocytes 
were transfected by Lipofectamine transfection with a control plasmid, containing a promoterless luciferase gene, 
with the nkx-luc plasmid that expresses a luciferase reporter gene under control of the the nkx2.5 promoter region. 
The des-siRNA plasmid was co-transfected with the nkx-luc vector in order to test the effect of desmin knock down 
by the desmin siRNA on the nkx2.5 promoter activity. All cells were futhermore transfected with a Renilla 
luciferase expressing plasmid, which is constantly expressed in all transfected cells. 48 hours after transfection, the 
cells were lysed and Luciferase activity was measured. The Luciferase signals were divided by the Renilla signals 
in order to eliminate fluctuations because of different cell counts or different transfection efficiencies. The 
experiment was made once in duplicates. 
 
3.2. Characterisation of Cardiovascular Progenitor Cells 
Different groups already succeeded in the isolation of somatic stem cells of the heart 
(Beltrami et al., 2003; Oh et al., 2003; Oyama et al., 2007; Pfister et al., 2005), 
however they have never been able to maintain the cells in culture for more than a few 
passages. Wiedner and Weber (Wiedner, 2008) succeeded in the isolation of stable 
cardiovascular progenitor cell (CVPC) lines, which express stemness factors as well as 
myocardial genes in the undifferentiated state. Therefore it can be assumed that they 
do not have the same potential as ESCs. They seem to be already committed to the 
cardiac lineage but still have stem cell character. CVPCs of passage 67 still form CBs 
comparable to CBs of early passages (Fig. 20) and they still differentiate to beating 
cardiomyocytes, although only at an extent of 50% compared to the early passages. 
They were already passaged for over 80 passages under continuous cryo-preservation. 
0
5
10
15
20
25
Lu
ci
fe
ra
se
/R
en
ill
a
 
re
la
tiv
e 
to
 
co
n
tr
o
l
pGL3b (control)     +             –                               –  
nkx-luc      –             +                               + 
des-siRNA     –             –                               + 
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Fig. 20 Cardiac Bodies of passage 16 and passage 67 CVPCs. Cardiovascular progenitor cells of an early 
(p 16, A) and late (p 67, B) passage were differentiated in cardiac bodies. Pictures were taken on day 16 
of development.  
 
 
 
 
 
 
 
3.2.1. Differentiation Potential of CVPCs 
When grown on feeder cells, CVPCs act like stem cells. They stay in a self-renewal 
mode and proliferate without differentiating to any other cell type. In the absence of 
feeder cells CVPCs start differentiating. The differentiation potential of ESCs was 
examined by growing the aggregates in hanging drop cultures to form embryoid bodies 
(EBs). This well established method also works for CVPCs. They form cardiac bodies 
(CBs) and this procedure is the best way of determining and examining the 
differentiation state of the cells. It could be seen, that CVPCs grown in aggregates 
without feeder cells exclusively differentiate to rhythmically contracting 
cardiomyocytes (CMCs), slowly contracting smooth muscle cells (SMCs), and 
endothelium-like cells (ETCs), the three major cell types of the adult heart. We never 
observed any nerve-like structures, skeletal muscle cells or erythrocytes even at very 
late developmental stages. Day 26 A5 CBs were stained with the cardiac marker gene 
cardiac Troponin T and DAPI (Fig. 21 A). Cardiac Troponin T is part of the Troponin 
complex in heart muscle cells, it links Tropomyosin to Troponin C. Cardiomyocytes 
build a network of contracting cells and have very tight cell-cell interactions which 
could be shown by staining the cells with Connexin 43, a gap junction protein (Fig. 21 
B). 
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Fig. 22 Comparison of day 9 EBs and CBs. Bright field images of AB2.2 EBs (A) and A5 CBs (B) on day 9 of 
development. Arrow indicates area with first beating cardiomyocytes in EBs. 
Fig. 21 Immunoflurescence of differentiated CVPCs. Cardiomyocytes in day 26 cardiac bodies were stained with 
cardiac TroponinT (green, A and B) and connexin 43 (red, B).  
3.2.2. Comparison of CVPC to ESC Differentiation 
When EBs were compared to CBs in regard to morphology, it was detected, that EBs 
formed a hourse-shoe like structure at early developmental stages, which has never 
been observed in CBs. CBs were larger and they showed faster cell spreading (Fig. 
22). EBs usually started beating in a distinct area next to the axis (Fig. 22 A, arrow) 
and then cardiomyocyte formation spreaded at the edge of the EB. In contrast to EBs, 
first cardiomyocytes started appearing on various areas in CBs at the same time and 
then started spreading inwards. 
To observe the beating potential of ESCs and CVPCs, aggregates were made of the 
two cell types. The number of beating bodies was counted every day for 34 days. First 
cardiomyocytes started beating in EBs on day 8 of development, whereas in CBs 
beating cells could only be detected from day 11 on (Fig. 23). Cardiomyogenesis is 
delayed in CBs by approximately four days compared to EBs. However CMCs in CBs 
A B 
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Fig. 23 Development of CMCs in CBs and EBs. A5 CBs and AB2.2 EBs were made and the number of beating 
bodies was counted every day for 34 days. Cardiomyogenesis in aggregated CVPCs is delayed compared to 
aggregated ESCs by 4 – 6 days but CMCs stay active over a longer period of time. Data are means of three 
counted wells, approximately 15 aggregates per well.  
stayed active over a longer period of time. From day 28 on, no beating cells in EBs 
could be observed anymore whereas a high percentage of the counted CBs still had 
rhytmically contracting CMCs.  
 
 
 
3.2.3. Paracrine Influence of EBs on CBs 
It might be possible, that other cells in EBs produce cardiomyogenesis accelerating 
factors that are not provided to the same amount in CBs and therefore cause the earlier 
onset of CMC development in EBs compared to CBs. To test this hypothesis, and to 
detect whether those factors are secreted by EBs, CBs were cultured in the presence of 
EBs. Therefore, CBs and EBs were made and on day 4.7 CBs were transferred to 6 
well plates and EBs were placed onto sieve inserts which were put into the wells of the 
6 well plate. As controls, CBs were rinsed onto sieve inserts as well and cultured 
above CBs. Therefore, both, cardiac and embryoid bodies had the same medium and 
factors secreted by embryoid bodies could influence CMC development in CBs. There 
was no influence on cardiomyogenesis detectable when CBs were co-cultured with 
EBs (Fig. 24). This suggests, that secreted factors are not the main reason for the 
earlier onset of cardiomyogenesis in EBs. 
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Fig. 24 Paracrine influence of EBs on CBs. EBs were cultured in sieve inserts in the same wells as CBs and the 
possible paracrine effect of factors secreted by EBs was tested. As a control, CBs were as well cultured in sieve 
inserts above CBs. Data are means of three counted wells, approximately 15 aggregates per well. 
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3.2.4. Extent of CMC Development in CBs and EBs 
Cardiomyogenesis is delayed in CBs compared to EBs (Fig. 23). However, the 
magnitude of CMC formation is potentiated in CBs. In EBs, small areas on the edge of 
the body started beating and this beating spreaded on the boarder of the EB. 
Contraction in CBs started approximately four days later, however contracting 
cardiomyocytes developed all over the CB and under the light microscope it seemed as 
if the entire aggregate contracted. This difference in the extent of CMC formation was 
visualized by indirect immunofluorescence staining of EBs and CBs for the cardiac 
marker gene cTNT. EBs and CBs were fixed on 10 cm plates on days where maximum 
beating activity was observed (day 11 and day 15 respectively). Bright field and 
fluorescence images were made (Fig. 25). Only few fluorescent cells were seen in the 
EB (Fig. 25 B). Those cells reflect the amount of differentiated cardiomyocytes in 
EBs. Since CBs were taken on day 15, only the central area of the CB is shown (Fig. 
25 C). The fluorescent image of the CB (Fig. 25 D) shows that the whole CB was 
pervaded by cTNT positive cells, cardiomyocytes built a network spanning the whole 
CB. 
This was also tested by Fluorescence Activated Cell Sorting (FACS). Therefore, 
AB2.2 EBs and A5 CBs were made and used on day 11 and day 15 respectively. EBs 
and CBs were trypsinised and incubated with an antibody against the cardiac marker 
gene cTNT and stained cells were measured in the FACS machine. The amount of 
stained cells was four times higher in CBs than in EBs (Fig. 26). The observation 
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Fig. 26 Fluorescence Activated Cell Sorting of cTNT stained AB2.2 EBs and A5 CBs. EBs and CBs were made 
of AB2.2 and A5 cells respectively. On days where maximum beating activity was observed (day 11 and day 
15), EBs and CBs were trypsinised, stained with cTNT and fluorescent cells were measured. The experiment was 
made three times, data are results of the third, optimized experiment. 
Fig. 25 Extent of CMC development in CBs and EBs. Aggregated ESCs and CVPCs were fixed on days of 
maximum beating activity (day 11 and day 15 respectively). CMCs were stained by indirect immunofluorescence 
staining with cardiac Troponin T (cTNT) and secondary FITC conjugated antibodies. Bright field image of whole 
EB (A) and fluorescence image of cTNT positive cells (B) are shown. (C) Bright field image of central area of day 
15 CB. (D) Fluorescence image of day 15 CB. 
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under the fluorescent microscope as well as the FACS experiment both show that 
CVPCs differentiate to highly cardiomyocytes-enriched bodies compared to ESCs. 
 
. 
37 
 
3.3. Effect of SPARC on CVPCs 
Secreted protein acidic and rich in cystein (SPARC) is a matricellular glycoprotein 
which is highly expressed and plays an important role during fetal development. It is 
also crucial in remodelling and tissure repair (Brekken et al., 1999). SPARC has a 
positive influence on ESC differentiation. It accelerates and amplifies 
cardiomyogenesis when added on days 7 – 10 of EB development (Stary et al., 2005). 
Neutralising α -SPARC antibodies show the opposite effect, they cause a decrease of 
cardiomyogenesis. Furthermore SPARC enhances the expression of the cardiac marker 
gene nkx2.5 in ESCs (Stary et al., 2005). The aim of the following experiments was to 
test the effect of SPARC on cardiomyogenesis in CVPCs.  
3.3.1. Secretion of SPARC during CB Differentiation 
We first had to determine which minimum concentration of SPARC had to be added to 
the cells in order to evoke a cellular response. Stary et al. (2005) used 3 µg/ml of 
recombinant SPARC. However, CVPCs already express SPARC in an undifferentiated 
state (Fig. 27 A) (Hoebaus, 2009) as well as upon differentiation. Therefore, the 
SPARC concentration in the medium of the differentiating cells had to be determined. 
This was done by DotBlot analysis. A5 CBs were made and supernatant of the CBs 
was taken every day from day 6 till day 14. The supernatant was directly blotted in a 
dilution series (1:1, 1:2, 1:4, 1:8) to a nitrocellulose membrane and recombinant 
SPARC protein of different known concentrations was blotted to the membrane as 
well. The membrane was stained with α-SPARC antibodies and detected. A5 cells 
produced the highest concentration of SPARC at the beginning of differentiation. The 
intensities of the dots were compared to those of recombinant SPARC of known 
concentrations. On day 6, a SPARC level of about 0.3 µg/ml was detected and 
afterwards the SPARC concentration decreased in the course of differentiation (Fig. 27 
B). Therefore, SPARC seems to be most important in early stages of differentiation 
and the concentration used in previous experiments with ESCs of 3 µg/ml is sufficient 
to induce an effect in CVPCs as well. 
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Fig. 27 Concentration of SPARC in A5 supernatant. Supernatant of undifferentiated A5 cells 2 hours after medium 
change was taken (A) (Hoebaus, 2009) and supernatants of A5 CBs were taken from day 6 till day 14 (B). They 
were blotted on a membrane in a dilution series (1:1, 1:2, 1:4, 1:8) and known concentrations of recombinant 
SPARC was blotted to the membrane as well. Detection was made using α-SPARC antibodies. 
3.3.2. The Influence of SPARC Addition on CB Development at different 
Time Points 
In EBs, SPARC addition had the most prominent effect when added on days 7 – 10 of 
differentiation (Stary et al., 2005). However, differentiation of ESCs differs from that 
of CVPCs and therefore SPARC might influence cardiomyogenesis at different time 
points in the two cell types. To test the time frame when SPARC influences 
cardiomyogenesis in CVPCs to the highest degree, neutralising α-SPARC antibody 
was added to A5 CBs at different time points and beating activity of the CBs was 
observed (Fig. 28).  
SPARC inhibition at all tested time points delayed the onset of cardiomyogenesis. 
When α-SPARC was added to CBs on days 7 – 10 and 10 – 13 first CMCs were 
formed 1 and 1.5 days later than in the untreated CBs. However, the extent of beating 
CBs was similar to A5 control CBs, 90 – 100% of the CBs formed beating CMCs. 
When α-SPARC was added earlier in development on days 4.7 – 7, cardiomyogenesis 
was not only delayed but also reduced. Only about 60% of the counted CBs contained 
contracting cardiomyocytes (Fig. 28). In the DotBlot experiment we detected, that the 
cells themselves produce higher concentrations of SPARC at early stages of 
A B 
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Fig. 28 Effect of α-SPARC on CB differentiation. A5 CBs were made and neutralising α-SPARC antibody was 
added on days 0-4.7, 4.7-7, days 7-10 and days 10-13. Results are displayed in a graph, values are means of 3 wells, 
15 counted CBs per well (A) and bar diagram (B, Auner, H.). 
A 
B 
development and here we show, that early inhibition of SPARC has the most severe 
phenotype. We chose the time frame of days 4.7-7 for SPARC addition in further 
experiments. 
3.3.3.  Effect of SPARC and α-SPARC on CB Differentiation 
In the following experiment, the influence of SPARC and α-SPARC on days 4.7 – 7 on 
the differentiation potential of CBs was investigated. A5 CBs were made, rinsed on 
day 4.7 and either 3 µg/ml recombinant SPARC or neutralising α-SPARC antibodies 
(1:100) were added. The medium was changed on day 7. They were imaged under the 
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Fig. 30 Influence of SPARC and α-SPARC on CB differentiation. A5 CBs were made and rinsed on day 4.7 onto 
gelatine coated plates. At the same time, 3 µg/ml SPARC and neutralising α-SPARC antibodies (1:100) 
respectively were added to the wells. They were incubated at 37°C. Medium was changed on day 7 and the 
number of beating CBs was counted every day until day 20 of development. Data are means of two wells, 15 
counted CBs per well. 
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Fig. 29 Darkfield images of control, SPARC and α-SPARC treated A5 CBs. A5 CBs were made and treated with 
0.3 µg/ml SPARC and with neutralising α-SPARC antibodies (1:100) on days 4.7 – 7. Bright field images were 
made on day 8 of A5 control CBs (A), SPARC (B) and α-SPARC (C) treated CBs. 
light microscope on day 8 (Fig. 29) and the number of contracting CBs was counted 
every 24 hours until day 20 of development (Fig. 30). CBs treated with SPARC looked 
similar to the control A5 CBs in regard to size and shape. The α-SPARC CBs however 
were smaller, they seemed to be hampered in growth and development (Fig. 29). This 
result suggested, that α-SPARC has a negative influence on CB growth and 
development. 
The addition of α-SPARC antibody indeed delayed and reduced the formation of 
contracting cardiomyocytes (Fig. 30). First beating was observed one day later than in 
the control and SPARC treated CBs. Cardiomyogenesis was not only delayed but also 
reduced, 30% of the counted CBs never built any beating cardiomyocytes. Addition of 
Control        SPARC        α-SPARC 
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Fig. 31 Influence of SPARC and α-SPARC on CB differentiation. A5 CBs were made and were rinsed on day 4.7 
onto gelatine coated plates. At the same time, 3 µg/ml SPARC and neutralising α-SPARC antibodies (1:100) 
respectively were added to the wells. They were incubated at 37°C. Medium was changed on day 7 and the number 
of beating CBs was counted daily. The mean of the percentage of beating CBs on days 11 – 13 was calculated. Data 
are means of two wells, 15 counted CBs per well. 
SPARC caused the opposite effect, it enhanced cardiomyogenesis. First beating 
activity was observed on the same day as the control CBs, but a higher percentage of 
CBs developed contracting CMCs at the very beginning of differentiation (Fig. 30). 
From day 15, 100% of both, untreated and SPARC treated CBs developed beating 
activity.  
The bar diagram in Figure 31 shows the mean of the percentage of beating CBs from 
days 11 – 13. Addition of SPARC resulted in the enhancement of cardiomyogenesis at 
the beginning of differentiation. Addition of α-SPARC caused a significant 
downregulation of contracting CBs. On days 11 – 13, only one third of beating CBs 
was observed compared to the control and SPARC CBs. 
3.3.4. Effect of SPARC on Wnt Signalling 
The previous experiment showed, that SPARC promotes cardiomyogenesis in CVPCs. 
However, the way in which SPARC influences differentiation is not known yet. We 
wanted to determine a signalling pathway through which SPARC influences 
cardiomyogenesis. Integrin α/β was found to be a candidate receptor for SPARC (Nie 
et al., 2008) and ILK activity is modulated by SPARC (Barker et al., 2005). ILK might 
act through modulating GSK3 activity, therefore interfering with Wnt signalling. 
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Fig. 32 Effect of GSK3α/β inhibition on β-catenin activity. A5 CVPCs were transfected with TCF/LEF-luc 
plasmid, containing a luciferase gene under control of a TCF/LEF binding sites promoter. Transfected cells were 
treated with 3 µM CHIR99021, an inhibitor of GSK3α/β and 48 hours after transfection Luciferase activity was 
measured. Data are means of four experiments. 
We wanted to investigate whether SPARC signalling influences the Wnt pathway and 
modulates activity of β-catenin. For this approach we used the TCF/LEF-luc reporter 
plasmid, which contains a luciferase gene under control of a TCF/LEF binding sites 
regulated promoter. TCF/LEF sites are sequences recognised and bound by β-catenin. 
This binding results in an activation of the promoter containing TCF/LEF sites. 
Therefore, the reporter gene expression reflects the level of active β-catenin in the cell.  
The level of β-catenin in the cell is regulated by the Glycogen Synthase Kinase 3 α/β 
(GSK3α/β). The active kinase phosphorylates β-catenin which results in its 
degradation. Unphosphorylated β-catenin can translocate to the nucleus and act as a 
transcription factor. 
Firstly, we detected whether the Wnt signalling can be activated in A5 CVPCs. 
Therefore we inactivated GSK3α/β with its inhibitor CHIR99021. CHIR99021 inhibits 
kinase activity of GSK3α/β and β-catenin cannot be phosphorylated and degraded. A5 
CVPCs were transfected with the TCF/LEF-luc vector and as an internal control with 
the Renilla plasmid. Four hours after transfection the medium was changed and 3 µM 
CHIR99021 was added. The cells were incubated at 37°C and 48 hours after 
transfection Luciferase activity was measured. GSK3α/β inhibition by CHIR99021 
caused a 14-fold increase of Luciferase activity (Fig. 32). Therefore, Wnt signalling 
can be activated in CVPCs by inhibition of GSK3α/β by CHIR99021. 
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Fig. 33 Effect of SPARC and α-SPARC on β-catenin activity. A5 CVPCs were transfected with the TCF/LEF-luc 
plasmid, containing a luciferase gene under control of a TCF/LEF binding sites promoter. Transfected cells were 
treated with 3 µg/ml SPARC, 3µg/ml SPARC + α-SPARC antibody (1:100) and with α-SPARC antibody (1:100). 
48 hours after transfection Luciferase activity was measured. Data are means of three experiments. 
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We then tested the effect of SPARC on Luciferase activity to get an indication about 
the signalling pathway through which SPARC influences cardiomyogenesis. 
Therefore, CVPCs were transfected with TCF/LEF-luc and Renilla plasmids and four 
hours after transfection the medium was changed and 3 µg/ml SPARC, 3 µg/ml 
SPARC toghether with α-SPARC (1:100) and α-SPARC alone were added, 
respectively. 48 hours after transfection, the cells were lysed and Luciferase activity 
was measured. Addition of recombinant SPARC to the transfected cells caused a 
reduction of Luciferase activity (Fig. 33). β-catenin could not activate the TCF/LEF 
regulated promoter to the same extent as in the control cells. This leads to the 
assumption, that SPARC reduced the level of β-catenin that can translocate to the 
nucleus and act as a transcription factor. This effect was compensated by the addition 
of α-SPARC to the SPARC induced wells. α-SPARC inhibited SPARC and more 
Luciferase was expressed than in the SPARC treated samples (Fig. 33). Therefore it 
can be said, that the inhibitory effect was indeed caused by SPARC addition. When α-
SPARC was added to the cells neither an increase, nor a significant decrease was 
detected. Thus, addition of recombinant SPARC had a negative effect on the level of 
TCF/LEF-luc        +   +         +   + 
SPARC         –   +         +   – 
α-SPARC        –   –         +   + 
44 
 
free β-catenin in the cells, but SPARC inhibition by α-SPARC did not enhance β-
catenin signalling. 
3.3.5. Effect of SPARC on Gene Expression 
In the previous experiments it was detected, that SPARC has a positive influence on 
CB differentiation and that it might act through inhibition of β-catenin signalling. We 
then wanted to test which target genes are influenced by SPARC and how they change 
their expression after addition of SPARC.  
Therefore, A5 cells were split onto 24 well plates (1:3 ratio) and on the next day, 3 
µg/ml SPARC were added to the wells. RNA was isolated immediately, 2 hours and 3 
hours after addition of SPARC. RNA was reversely transcribed into cDNA and PCRs 
were made using primers recognising different genes of interest (Fig. 34). Nkx2.5 and 
MHCα are myocardial genes and it could be seen, that addition of SPARC caused an 
upregulation of their expression after 2 hours. The expression of the myocardial gene 
isl1 however was not influenced by recombinant SPARC. Mesp1 as a cardiovascular 
marker gene was slightly upregulated. Desmin was found to bind to the nkx2.5 
promoter in ESCs and differentiated CVPCs and overexpression of desmin accelerates 
heart cell formation in EBs (Hofner et al., 2007). Therefore it was interesting whether 
SPARC influences desmin expression and therefore enhances cardiomyogenesis. It 
was detected, that in the unstimulated A5 cells, no desmin mRNA was produced, but 
the addition of SPARC caused an increase in the desmin mRNA level in the cell. The 
next gene we were interested in was the mesodermal marker gene brachyury. 
Brachyury was upregulated after two and especially three hours of SPARC addition. 
Goosecoid is a gene involved in organising the embryo during early development and 
indicates differentiation. The undifferentiated control cells did not express this 
differentiation marker gene. After the addition of SPARC, the cells started producing 
goosecoid mRNA, the level increased between two and three hours after addition. 
Furthermore, we detected and increase in the mRNA level of Oct3/4 two and three 
hours after SPARC addition. 
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Fig. 34 Influence of SPARC on gene expression. 3 µg/ml recombinant SPARC was added to A5 CVPCs grown for 
one day on gelatine in monolayers. RNA was isolated of a control well, and 2 and 3 hours after SPARC addition. 
RNA was reversely transcribed into cDNA and PCRs were made with primers recognising different genes 
important in differentiation. A GAPDH PCR was made to show that the same amount of cDNA was taken of the 
three samples.  
3.4. GSK3α/β and MAPK Signalling in Cardiomyogenesis 
We have already tested, that SPARC enhances cardiomyogenesis and it influences the 
level of free β-catenin in the cell. Therefore, the Wnt signalling pathway seems to play 
an important role in cardiomyogenesis. We then wanted to investigate the influence of 
the GSK3α/β and MAPK pathways on cardiomyogenesis. 
Therefore, A5 CBs were made, and inhibitors of the two pathways of interest were 
added on different days of development. The MAPK signalling cascade was inhibited 
by the MEK inhibitor PD98059 (10 µM), the GSK3 pathway by CHIR99021 (3 µM). 
The small molecules were added to the CBs on days 0 - 4.7, days 4.7 - 7, days 7 - 10, 
and days 10 – 13. The number of beating CBs was counted every 24 hours until day 21 
of development. Both inhibitors did not influence cardiomyogenesis when added on 
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days 4.7 – 7 and days 10 – 13, respectively (data not shown). The onset of CMG and 
percentage of beating CBs was similar to the untreated A5 control cells. However at 
very early stages of development, PD98059 had a negative influence on 
cardiomyogenesis (Fig. 35 A). When the MEK inhibitor was added on days 0 – 4.7, 
the onset of contracting CMC formation was significantly delayed. First contracting 
cells in the CBs were observed two days later than in the control cells. In contrast, 
GSK3α/β inhibition on days 0 – 4.7 barely influenced cardiomyogenesis in CBs. 
GSK3α/β activity however seemed to be important at later stages of differentiation. 
When CHIR99021 was added on days 7 – 10, a drastic delay and reduction of 
cardiomyogenesis was detected (Fig. 35 B). The onset of CMG was delayed by 2.5 
days and 30% of all CBs never contained any cells that differentiated into contracting 
cardiomyocytes, even at later stages of development. In this time frame, PD98059 
addition did not influence CB differentiation. 
From these data, it can be reasoned, that at the very beginning of cardiomyogenesis 
(days 0 – 4.7 of CB development) the MAPK pathway plays an important role whereas 
GSK3α/β signaling can be inhibited without any effect. Later in development, on days 
7 - 10, MEK inhibition did not influence CMC formation, but GSK3α/β activity is 
necessary for proper differentiation of CBs. 
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Fig. 35 Effect of MAPK and GSK3α/β inhibition on CB differentiation. A5 CBs were made and were treated 
with 10 µM PD98059 (PD), a MEK inhibitor, and 3 µM CHIR99021 (CHIR), a GSK3 inhibitor. Inhibitor was 
applied on days 0 – 4.7 (A) and 7 – 10 (B). The CBs were incubated at 37°C and the percentage of beating CBs 
was calculated every day until day 21 of development. Data are means of three wells, approximately 15 counted 
CBs per well. 
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3.5. Generation of a Nkx2.5 – EGFP Reporter Cell Line 
Nkx2.5 is a very important gene in heart cell development. During cardiomyogenesis it 
is one of the earliest heart specific genes and transcription factors that is expressed. It 
is upregulated in CVPCs upon differentiation and therefore it would act as a good 
marker gene to monitor development of CVPCs to cardiomyocytes.  
The goal was to generate a CVPC line which carries an EGFP marker gene under the 
control of the nkx2.5 promoter. Therefore, whenever cells express nkx2.5, EGFP is 
produced which can be detected by western blotting, immunofluorescence microscopy 
and FACS. The effect of the addition of different factors supposed to influence 
cardiomyogenesis could be investigated with this reporter cell line in an easy way and 
optimal conditions for differentation could be determined. A control ESC line carrying 
an EGFP gene knocked into one allel of the nkx2.5 gene has already been established 
in our laboratory and the EGFP gene activity represents the nkx2.5 expression in the 
course of cardiomyogenesis. 
3.5.1. Homologue Recombination of A5 Cells  
The pCsx-EGFP-PP-DT vector (Hidaka et al., 2003) contains sequences homologue to 
the murine nkx2.5 gene but they are interrupted by an EGFP and puromycin resistence 
gene. When transfected to cells, the reporter and selection gene flanking sequences 
homologue to nkx2.5 can bind to the DNA and if homologue recombination occurs, the 
EGFP and puromycin genes are integrated into the genome (Fig. 36). 
A5 cells were electroporated with the linearized pCsx-EGFP-PP-DT plasmid. Feeding 
cells with medium containing puromycin (1 µg/µl) for seven days resulted in a 
selection for cells which integrated the vector into the genome. Two clones were 
picked on day 10 after electroporation, on day 16, 8 more colonies were picked. Five 
of the ten picked clones reached confluence and were named A5-Csx 1 – 5. 
Fig. 36 Nkx2.5-EGFP knock-in region. The pCsx-EGFP-PP-DT vector was linearised and brought into A5 cells by 
electroporation and with homologue recombination, the EGFP reporter gene and the puromycin resistence gene 
were knocked into the nkx2.5 gene (Hidaka et al., 2003). 
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Fig. 37 Detection of successful knock in of the pCsx-EGFP-PP-DT vector into the genomic region of the nkx2.5 
gene. PCRs were made with genomic DNA of A5 cells thought to carry an EGFP and puromycin resistence gene 
in one allel of the nkx2.5 locus. Primers were used recognising a sequence inside and outside the homolougously 
recombined pCsx-EGFP-PP-ST vector. A PCR product only occurs if the construct integrated into the genome in 
the desired way. 
3.5.2. Verification and Characterisation of A5-Csx Cell Lines 
To confirm that the vector was homolougously recombined into the nkx2.5 sequence 
and did not insert randomly into the genome, PCR primers were designed. One primer 
recognized a sequence in the puromycin resistance gene within the construct, the other 
one a sequence 3’ of the cassette in the nkx2.5 genomic region. Only if the construct 
integrated in the correct location, a PCR product of 1924 bp will occur. 
DNA of all five A5-Csx clones was isolated by Phenol/Chloroform extraction. As a 
positive control, DNA of the already established ESC line carrying one nkx2.5-EGFP 
allel, named MS15, was isolated as well. Furthermore, A5 and AB2.2 DNA served as 
negative controls. No PCR product was obtained for those two controls. In the MS15 
sample, a product of the correct length could be detected. The PCRs of all five clones 
resulted in a PCR product of the same length (Fig. 37), confirming that all clones carry 
an EGFP gene under control of the nkx2.5 promoter. 
Since one allel of the nkx2.5 locus is mutated in the A5-Csx cells, we wanted to 
differentiate the cells in CBs and compare them to A5 CBs in regard of beating to see 
whether cells are hampered in cardiomyogenesis due to the mutation in one allel. 
Furthermore, the expression of EGFP on different days of development has been 
observed by fluorescence microscopy. The same amount of cells was taken to produce 
A5 and A5-Csx4 CBs and the number of contracting CBs was counted daily. There 
was no difference in the first appearance of beating CMCs and in the number of 
rhytmically contracting A5 and A5-Csx4 CBs. First contracting cardiomyocytes were 
observed on day 10 in both cell types and maximum beating activtiy was reached at 
day 14 of development (Fig. 38). The cells heterozygous for nkx2.5 did not show 
altered cardiomyogenesis in this setting. 
                    A5 Csx                        
1           2           3           4           5       MS15   A5   AB2.2  
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Fig. 38 Development of CMCs in A5 and A5-Csx4 CBs. A5 and A5-Csx4 CVPCs were aggregated to CBs and the 
percentage of beating bodies was calculated every day for 14 days. Data are means of two wells, 15 CBs per well. 
We next wanted to explore, whether A5-Csx cells express EGFP and therefore can be 
observed under the fluorescence microscope. CBs and EBs were made of A5-Csx2, 
A5, MS15 and AB2.2 cells. The MS15 EBs served as a positive control, AB2.2 and A5 
CBs were used as negative controls. After 13 and 14 days of development, EBs and 
CBs were observed under the fluorescence microscope (Fig. 39). Bright field and 
fluorescence images of MS15 EBs and AB2.2 EBs were taken. The AB2.2 EBs did not 
have any fluorescent cells. In MS15 EBs a picture of an area of beating 
cardiomyocytes was taken and exactly this area contained fluorescent cells. This 
means, that EGFP is expressed in those cells and thus, those cells express nkx2.5. 
The fluorescence of the A5-Csx2 and A5 CBs was analysed on day 14 by fluorescence 
microscopy (Fig. 40). Bright field as well as fluorescence images of beating areas of 
the CBs were taken. Many A5-Csx2 cells were fluorescent. However, having a look at 
the A5 negative control, a similar picture was seen. It seems that A5 CVPCs had a 
strong background fluorescence and thus, the additional EGFP fluorescence could not 
be detected. No conclusion could be drawn with this method about the nkx2.5 
expression in CVPC cells. 
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Fig. 39 Expression of EGFP in homolougously recombinated AB2.2 ESCs. EBs were made with MS15 and AB2.2 
cells. MS15 cells are ESCs which have an EGFP marker gene knocked into one allel of the nkx2.5 locus. 
Brightfield image (A) and fluorescence image (B) of MS15 EBs compared to brightfield image (C) and 
fluorescence image (D) of AB2.2 EBs on day 13 of development.  
Fig. 40 Expression of EGFP in A5 CVPCs. CBs were made with A5-Csx2 and A5 cells. A5-Csx2 cells are CVPCs 
which have an EGFP marker gene knocked into one allel of the nkx2.5 locus. Brightfield image (A) and 
fluorescence image (B) of A5-Csx CBs compared to brightfield image (C) and fluorescence image (D) of A5 CBs 
on day 14 of development. 
Therefore, we tried to amplify the EGFP signal by indirect immunofluorescence 
staining with GFP antibodies and secondary FITC-labelled antibodies. However, even 
with this amplification, we did not detect any difference between the A5-Csx and A5 
cells (data not shown). However, immunofluorescence staining was made on day 14 of 
development, maybe nkx2.5 expression and therefore EGFP expression was already 
low at this stage of development and therefore even harder to detect. 
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Fig. 41 Western Blot of A5 and A5-Csx4 cells with GFP antibodies. A5 and A5-Csx4 CBs were made and protein 
was isolated from day 8 till day 14. 35 µg protein per lane were loaded on a gel, blotted to a nitrocellulose 
membrane and the proteins were detected with α-GFP antibodies. 
We then tried to detect the EGFP expression by Western Blotting. Therefore, A5-Csx4 
CBs and A5 CBs were made and proteins were isolated from CBs on days 8 – 14. 
Proteins were detected with α-GFP antibodies. The A5 samples never showed a GFP 
signal at any time whereas the A5-Csx4 samples were GFP positive at all measured 
time points (Fig. 41). These data suggest that nkx2.5 is expressed in A5-Csx4 cells 
from days 8 – 14. 
Searching for a method suitable to measure quantitative differences in the EGFP 
expression of A5-Csx cells, we tried to make a FACS analysis of A5 and A5-Csx cells. 
The settings for the FACS analysis could be chosen to disregard autofluorescence and 
only EGFP fluorescence is taken account of. 
A5 and A5-Csx4 CBs were made, on day 9 of differentiation they were trypsinised, 
resuspended in PBS and the number of fluorescent cells in the two samples was 
measured. In the A5 sample no GFP positive cells were measured. However 15% of 
the A5-Csx4 cells expressed GFP (Fig. 42).  
This method seems to be the most sensitive and is the most promising approach to 
investigate differences in the expression of nkx2.5 in the course of differentiation. 
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Fig. 42 FACS of A5 and A5-Csx4 CBs. CBs were made of A5 and A5-Csx4 CVPCs. On day 9 of 
development CBs were trypsinised, resuspended in PBS and GFP positive cells were counted by FACS. 
The experiment was made once. 
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4. Discussion 
The murine heart comprises cardiac stem cells which are supposed to be able to 
regenerate small areas of dead tissue. However, the regenerative potential of those 
cells is not sufficient to cure injured hearts. Understanding the mechanisms activating 
those dormant cells to differentiate and to replace injured cells would be a great 
achievement for cell based therapy. Here, the isolation of stable cardiovascular 
progenitor cell (CVPC) lines and the establishment of an in vitro model to determine 
differentiation conditions and factors influencing cardiomyogenesis is shown. The 
isolated CVPCs had the potential to differentiate exclusively to cardiomyocytes, 
smooth muscle, and endothelial cells and therefore are restricted to the cardiac lineage. 
Adaptation of the embryoid body (EB) formation method from ESCs resulted in a 
reproducable system for differentiation of CVPCs in cardiac bodies (CBs). A highly 
increased amount of beating cardiomyocytes was observed in CBs compared to EBs, 
however the onset of CMG was delayed. We furthermore report the generation of a 
GFP positive reporter cell line, reflecting the expression level of the early cardiac 
marker gene nkx2.5. The protein Desmin was identified to bind to the nkx2.5 promoter 
region in ESCs as well as in differentiated CVPCs and pCMCs. Furthermore, SPARC 
was shown to have a positive influence on CMC formation by upregulating cardiac 
specific gene expression. In addition, SPARC regulated Wnt signalling resulting in a 
decrease of nuclear β-catenin. It was further shown, that Wnt and MAPK signalling 
pathways play an important role in CMG at different time points of differentiation.  
4.1. Isolation, Maintainance, and Differentiation Potential of Stable 
CVPC Lines 
Recently, it was suggested that cardiac stem cell reside in the adult heart and several 
groups succeded in their isolation (Beltrami et al., 2003; Laugwitz et al., 2008; Oh et 
al., 2003; Oyama et al., 2007). However, maintaining them in culture remained 
challenging. Here, a new approach for the isolation of stable CVPC lines is reported. 
Murine heart cells were co-cultured with ESCs and feeder cells in order to mimic niche 
conditions (Wiedner, 2008). This imitation of natural environment kept CVPCs in a 
condition, allowing self-renewal and maintainance in culture for indefinite time. 
Therefore, they serve as a good starting material to study differentiation and 
cardiomyogenesis influencing factors since the cells remain identical for all 
experiments. CVPCs express the three stemness factors sox2, nanog, and oct3/4 at 
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comparable amounts to murine ESCs. The combined expression of these three 
transcription factors allows CVPCs to stay in a self-renewal mode when grown on LIF 
secreting fibroblasts, they can be expanded in culture without losing pluripotency. 
Simultanously, the expression of nkx2.5 and MHC-α was detected in an 
undifferentiated state (Hoebaus, 2009), showing a predisposition to the cardiac lineage. 
Upon LIF deprivation, CVPCs start to differentiate, losing their stem cell potential. 
These cell lines have already been cultured for more than 80 passages under continous 
cryo-preservation maintaining their potency to self renew and to form beating CMCs 
upon differentiation. The adaption of the protocol for the production of EBs (Weitzer 
et al., 1995) to produce CVPCs derived CBs provided a controllable and highly 
reproducable system for the study of differentiation to CMCs. CVPCs aggregated in 
the hanging drop culture without attachment to an artificial surface. In CBs, CVPCs 
differentiated exclusively to cardiomyocytes, smooth muscle cells and endothelial 
cells. Cardiomyocytes built networks with tight connexin 43 positive cell – cell 
interactions. We never observed any nerve-like structures, skeletal muscle cells, 
adipocytes, or erythrocytes. Compared to EBs, CBs had a less structured and point 
symmetic development. First beating cells in CBs were observed on day 12, which was 
approximately four days later than in EBs. The earlier onset of CMG in EBs was not 
primarily caused by secreting factors produced by the EBs, since co-culture of CBs 
with EBs did not accelerate CMG in CBs. However, under the same culture conditions 
CMCs in CBs stayed active over a longer period of time. Contraction in EBs could not 
be observed after day 28 of differentiation, whereas still a high percentage of CBs 
consisted of contracting CMCs. We also showed, that the extent of CMC development 
in CBs was much potentiated compared to EBs. In EBs only small areas with 
rhytmically contracting cells were observed, whereas in CBs, beating CMCs built a 
network spanning the entire CB. The continuous self-renewal of CVPCs, their limited 
differentiation potential, and the high degree of CMC formation makes these cells 
good candidates for cell therapy. 
4.2. Generation of a Nkx2.5-EGFP Reporter Cell Line 
Nkx2.5 is the most important early cardiac gene in first heart field CMG. Forced 
expression of Nkx2.5 is sufficitent to enhance cardiogenesis in murine ESCs (David et 
al., 2009). It is upregulated during differentiation of CVPCs and would therefore serve 
as a good marker gene to keep track of CVPCs differentiating to CMCs. Here we 
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report the generation of a stable CVPC line carrying an EGFP reporter gene in one 
allel of the nkx2.5 locus. Expression of EGFP was controlled by the nkx2.5 promoter 
and reflected the nkx2.5 expression in the cells. Two previously found aspects had to 
be taken into account before differentiating these cells. Firstly, it was shown that 
heterozygous mutation of nkx2.5 negatively influenced cardiac morphogenesis and 
blocked atrioventricular conduction (Biben et al., 2000). Secondly, it was detected, that 
EGFP binds to myosin. This binding had a negative effect on the contractile function 
of cells (Agbulut et al., 2007). However, differentiation of the generated nkx2.5-EGFP 
cells did not show differences in their cardiomyogenic potential compared to CVPCs 
which is in accordance to findings of other groups working with similar cell lines 
(Hidaka et al., 2003). Since the cardiogenic potential was not influenced, the 
generation of a nkx2.5-EGFP reporter cell line provided a useful in vitro culture 
system to monitor nkx2.5 expression during development and the effect of several 
CMG influencing factors. The GFP signal however was very weak and for in vitro 
experiments, FACS analysis was shown to be the most promosing detection method. 
Further copies of nkx2.5 promoter – EGFP integrated into the genome could enable the 
detection of EGFP in CVPCs. The nkx2.5-EGFP cell line could also be used to track 
the fates of CVPCs and differentiating cardiomyocytes in vivo. Injection of EGFP-
positive CVPCs into the murine heart could show the reintegration and regenerative 
potential of those cells in the adult, injured heart.  
4.3. Influence of Desmin on nkx2.5 
The intermediate filament type III protein Desmin was shown to upregulate the 
expression of the cardiac marker gene nkx2.5 during mesoderm formation in EBs 
(Hofner et al., 2007). However, the mechnism how this activation works is not known 
yet. Here, we detected a physical interaction of Desmin with the nkx2.5 promoter on 
day 6 and day 8 in wild type EBs. First beating in wild type EBs occured on days 6.5-
7.5. In Desmin overexpressing EBs (DC6 ESCs) an interaction was already detected 
on day 5, and remained on day 6 and day 7. The interaction started and also ended one 
day earlier than in the wild type cells. The desmin overexpressing EBs started beating 
one day earlier than the wild type EBs, first beating could normally be seen from day 
6.5 to day 7. In wild type EBs, as well as in Desmin overexpressing EBs Desmin 
interaction with the nkx2.5 promoter could be detected one day before the onset of 
contraction. It seems as if the development of heart cells is shifted one day in advance 
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in DC6 cells since the interaction as well as the beating was detected one day earlier 
than in wild type cells. These results suggest a correlation between binding of Desmin 
to the nkx2.5 promoter and cardiomyocyte formation. This interaction might be a 
necessary step for initiation of cardiomyogenesis. However, in wild type and DC6 EBs 
no or very little interaction of Desmin and the nkx2.5 promoter was oberserved on the 
day where first beating occurred. Probably, for contraction, a reconstruction of the 
intermediate filament structure has to occur and for this short time, Desmin is recruited 
out of the nucleus. At later stages of differentiation no interaction was observed, 
Desmin’s action as a transcription factor might be redundant. The 1B44 EBs whose 
Desmin N-terminus is deleted did not show any interaction of Desmin with the nkx2.5 
promoter. The Desmin amino-terminus was detected to be be important for 
cardiomyogenesis (Hollrigl et al., 2002). Our results provide evidence, that the N-
terminus is important for DNA binding. The lack of DNA – nkx2.5 promoter 
interaction might be a reason for the negative effect of the Desmin amino-terminus 
deletion on cardiomyogenesis.  
We then tested whether Desmin - DNA interaction occurs in CVPCs and in pCMCs. 
ChIP was made of undifferentiated and differentiated CBs (day 17). Interaction of 
Desmin with the nkx2.5 promoter was seen in the differentiated CBs which already 
formed beating CMCs, however no binding occurred in the undifferentiated samples. 
Therefore it seems that the interaction takes place in the course of development and 
might be an important step in heart cell formation. In day 17 CBs, already a high 
percentage of CBs formed rhytmically beating clusters. At this time point, the Desmin 
– nkx2.5 promoter interaction already stopped in EBs. Differentiation of CVPCs in 
CBs results in the production of CMC at a high level, however the onset of CMG is 
delayed. CMCs in CBs are furthermore active over a much longer period of time 
compared to CMCs in EBs and the production of further CMCs might be induced at 
later time points as well. Therefore, it might be reasonable, that the interaction in CBs 
still occurs at later stages of differentiation. Furthermore, we found Desmin bound to 
the nkx2.5 promoter region in differentiated heart cells of new born mice. This 
provides another evidence for the hypothesis stating that the longer CMCs stay active, 
the longer Desmin is bound to the nkx2.5 promoter. 
Nkx2.5 is already expressed in undifferentiated CVPCs. However, the degree of its 
expression is very low as long as cells are obtained with signals for self-renewal. 
Differentiation inducing signals could result in binding of Desmin to the nkx2.5 
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promoter and thereby increase the level of expressed nkx2.5 which in turn might lead 
to commitment and final differentiation. 
The effect of the Desmin-nkx2.5 promoter interaction on gene expression was 
examined by transfection of C2C12 cells with plasmids containing a luciferase 
reporter gene under the control of the nkx2.5 promoter. Downregulation of desmin by 
desmin siRNA and coherent downregulation of nkx2.5 expression would proof the 
Desmin – specific effect on nkx2.5 promoter activity. We showed that the nkx2.5 
promoter was indeed active in C2C12 myoblasts and we could demonstrate a 
downregulation of reporter gene expression after desmin knock down. These data are 
in line with our ChIP data from which we hypothised that binding of Desmin to the 
nkx2.5 promoter enhances its activity resulting in CMC differentiation. They are also 
in accordance with Hofner et al. (2007) who revealed Desmin as a positive regulator of 
cardiomyogenesis. However, desmin overexpression decreased promoter activity. This 
corresponds to studies suggesting a negative feedback loop of Desmin when reaching a 
certain concentration in the cells (Hoebaus, 2009). In primary cardiomyocytes, desmin 
knock down did not influence promoter activity. In earlier ChIP experiments it was 
detected, that Desmin is bound to the nkx2.5 promoter in day 0 pCMCs. Here, 
downregulation of Desmin in day 5 pCMCs did not alter nkx2.5 expression. In the 5 
days further developed cells Desmin might not have an influence on nkx2.5 expression 
anymore. 
4.4. Influence of SPARC on CVPCs 
Recombinant SPARC was described to enhance CMG in ESCs (Stary et al., 2005). 
ESCs express SPARC on mRNA level but SPARC could not be found as a secreted 
protein (Stary et al., 2005). The addition of recombinant SPARC to EBs on days 7 – 10 
increased the amount of differentiated CMCs whereas neutralizing α-SPARC antibody 
showed the opposite effect (Stary et al., 2005). Unlike ESCs, undifferentiated CVPCs 
secrete SPARC at high levels (Hoebaus, 2009) and in the course of CB development, 
SPARC secretion decreased. Assuming a positive influence for SPARC on CMG, 
SPARC might therefore be important in early steps of differentiation. This was 
affirmed by detecting a time dependent negative influence of neutralizing α-SPARC 
antibody and a positive effect on CMG upon addition of recombinant SPARC to CBs 
on days 4.7 – 7. Despite the fact that the onset of CMC formation in CBs is delayed 
compared to EBs, SPARC influenced CMG at earlier time points in CBs than in EBs. 
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CVPCs might have to be provided with SPARC earlier in differentiation. The ground 
state of CVPCs is already progressed in development compared to the ground state of 
ESCs. ESC differentiation might firstly go through progenitor cell formation and at 
this stage, SPARC can positively influence CMG. However, despite addition of 
SPARC to CBs, the onset of CMC formation is delayed compared to EBs, therefore 
SPARC is not able to replace the microenvironment and possible niche conditions that 
are mimicked in EBs. 
To gain better insights into the mode of SPARC action, the short time effect of SPARC 
on genes involved in differentiation was tested by detecting their mRNA level two and 
three hours after addition of recombinant SPARC. Several genes altered in their 
expression pattern upon SPARC addition could be identified. We detected an increase 
in expression of the early cardiac marker gene nkx2.5. MHCα as a late gene in cardiac 
development was not significantly upregulated, giving another reason for classifying 
SPARC as a protein involved in early CMG. The myocardial gene isl1 expression was 
not changed upon SPARC addition. Nkx2.5 is expressed in first and second heart field 
progenitors, whereas isl1 was identified as the key transcriptional regulator of the 
second heart field progenitor cell lineage (Laugwitz et al., 2008). This provides 
evidence that SPARC may promote differentiation of first heart field progenitors or 
that CVPCs are progenitor cells of the first heart field. In addition to the other cardiac 
markers, SPARC slightly upregulated the expression of mesp1, which is a master 
regulator sufficient to induce cardiovasculogenesis in ESCs (David et al., 2008). 
Desmin was found to bind the nkx2.5 promoter in EBs and differentiated CVPCs and 
desmin overexpression enhanced CMG in EBs (Hofner et al., 2007). Here, an increase 
of desmin mRNA after two and three hours of SPARC addition was detected. A link 
between two positive regulators of CMG was established. SPARC might increase 
Desmin protein concentration. Desmin was shown in earlier ChIP experiments to bind 
to the nkx2.5 promoter region in ESCs, differentiated CVPCs and pCMCs. It was 
further identified to positively influence Nkx2.5 expression in C2C12 myoblasts, 
suggesting the possibility that Desmin might activate the expression of the cardiac 
marker as well in ESCs and CVPCs. Therefore, nkx2.5 gene expression enhancement 
by SPARC might act via desmin upregulation. In addition to cardiac markers, SPARC 
upregulates the expression of the differentiation inducing factor goosecoid. It is 
expressed in vivo during early development and is involved in organising the embryo, 
indicating differentiation. Furthermore the mesodermal marker gene brachyury was 
60 
 
upregulated as well. A link might be established between the upregulation of desmin 
and brachyury, since Desmin was shown to upregulate Brachyury expression during 
mesoderm formation (Hofner et al., 2007). These results suggest that SPARC promotes 
myocardial differentiation by upregulating the expression of cardiac marker genes of 
the first heart field. However, SPARC might as well play an important role earlier in 
development during differentiation of other cell types by upregulating markers 
important for organisation of the embryo and for mesoderm formation. 
4.5. MAPK and Wnt Signalling in CVPCs 
An important step in elucidating mechanisms involved in CMG is the detection of 
signalling pathways important for proper development. We could determine the 
contribution of two pathways involved in several developmental mechanisms, the 
MAPK and the Wnt pathway, to CMG. Inhibitor of MAPK pathway added at the very 
beginning of differentiation from days 0 – 4.7 delayed the onset of contraction in CBs. 
Inhibition at later time points did not affect CMG. This is in accordance with previous 
found results where activated ERK was detected during the first four hours after 
conjugation of xenopus animal cap (AC) and anterior endoderm (AE) explants. 
Inhibition of ERK in AC/AE explants during those four hours significantly reduced 
CMG whereas no effect was seen at later time points (Samuel and Latinkic, 2009). 
Therefore, CVPCs seem to activate the MAPK pathway at the very beginning of 
differentiation, which might be a necessary step for proper heart cell formation. The 
contribution of the second pathway, the Wnt signalling pathway, was tested by 
inhibition of GSK3. Inhibition of GSK3 resulted in an increase of free β-catenin in 
CVPCs which translocates to the nucleus. Elevated levels of active β-catenin 
transcription factors on days 7 – 10 of differentiation delayed the onset of CMG and 
reduced the number of beating CBs. At earlier stages of development GSK3 inhibition 
did not alter CBs differentiation. Therefore, Wnt signalling seems to be redundant at 
early stages of cardiomyocyte development and important later in differentiation. 
Kwon et al. (2007) reported canonical Wnt signalling as being a regulator for CMG 
during specific windows of development. Activation of the Wnt/β-catenin pathway 
after gastrulation in xenopus laevis embryos prevented cardiac differentiation (Samuel 
and Latinkic, 2009). Recent studies suggested that active β-catenin is necessary at 
early stages of CMG whereas it might have an inhibitory effect later in development 
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(Lin et al., 2007; Riazi et al., 2009). Our results affirm the assumption, that elevated 
nuclear β-catenin levels in CVPCs reduce CMG at later stages of development.  
Since the signalling pathway through which SPARC induces cellular responses is not 
known yet we tried to detect whether a link between SPARC and one of these two 
pathways influencing CMG could be established. The addition of recombinant SPARC 
downregulated the expression a luciferase gene under the control of a β-catenin 
regulated promoter. This negative regulation was reverted by neutralizing α-SPARC 
antibodies, proving evidence for the selectivity of the downregulation caused by 
SPARC. Since SPARC might therefore act through the transcriptional mediator β-
catenin, the binding of SPARC to integrin-β followed by activation of ILK (Barker et 
al., 2005; Weaver et al., 2008) could result in a modulation of GSK3β activity 
negatively influencing Wnt signalling and downregulating genes regulated by β-
catenin controlled promoters. Under the premise that SPARC enhances cardiac 
differentiation and decreases active β-catenin transcription factor, downregulation of 
nuclear β-catenin leads to enhanced CMG in CVPCs. These data are in contrast to 
results showing that β-catenin activity is necessary for specification, migration and 
expansion of progenitors of the second heart field (Cohen et al., 2007; Kwon et al., 
2007). Therefore, different signalling pathways are activated in CVPCs than in 
progenitor cells of the second heart field, classifying them into a distinct type of 
progenitor cells and providing another indication for an influence of SPARC on first 
heart field progenitors. The cardiac transcription factor Mesp1 was found to inhibit 
Wnt signalling by binding to the Wnt-inhibitor Dkk-1 (David et al., 2008). SPARC 
was shown to upregulate Mesp1 expression, providing another possibile explantation 
for its effect on β-catenin activity. 
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5. Conclusion 
The very limited regenerative potential of the heart makes stem cell therapy a new 
approach against cardiovascular diseases. The isolation of stable CVPC lines 
exclusively differentiating to cardiomyocytes, smooth muscle cells and endothelial 
cells, providing an unlimited, renewable source of identical cells, fulfilled a central 
challenge in the search for curing methods. CVPCs exclusively differentiate to cells of 
the adult heart and it is possible to get highly CMC-enriched cultures making them 
good candidates for cell therapy. The generation of a transgenic CVPC line carrying an 
EGFP gene in one allel of the nkx2.5 locus provided a good reporter cell line to study 
alterations of the expression of that early cardiac marker gene upon differentiation and 
addition of CMG influencing factors. Two proteins, Desmin and SPARC, could be 
identified as CMG influencing factors. Desmin protein enhances CMG and was found 
to bind to the nkx2.5 promoter in ESCs, differentiated CVPCs, and pCMCs. SPARC 
was detected to be a positive regulator of CMG by decreasing the promoter activity of 
β-catenin regulated genes in the cells and enhancing the expression of cardiac marker 
genes of the first heart field. It furthermore upregulates markers important for 
differentiation and mesoderm formation. MAPK signalling plays an important role 
immediately after initiation of differentiation whereas Wnt signalling is necessary for 
proper CMC formation at later stages of development.  
Further investigations of CVPCs will lead to a better understanding of early steps in 
CMG. It remains to be detected whether those cells have the ability to reintegrate into 
the murine heart. With the help of these cells, an important step towards the ultimate 
goal, the regeneration of injured or dead tissue by reactivating or reintegrating cardiac 
stem cells in vivo, can be made. 
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6. Material 
6.1. Enzymes 
Collagenase Wothington, USA 
DNAse I, RNase free Fermentas, Lithuania 
Pancreatin Sigma, USA 
Proteinase K Fluka, CH 
RiboLock RNase Inhibitor Fermentas, Lithuania 
RevertAidTM M-MuLV RT Fermentas, Lithuania 
Restriction Enzymes New England Biolabs, USA 
Taq DNA Polymerase Fermentas, Lithuania 
Trypsin LifeTechnologies, USA 
 
6.2. Chemicals for Cell Culture 
ß-Mercaptoethanol Loba, A  
Ampothericin B Invitrogen, USA  
D-Glucose Acros, B  
DMEM powder Gibco, USA  
DMSO (Dimethylsulfoxide) Sigma, USA  
Fetal Bovine Serum (FBS) HyClone, USA  
Fetal Bovine Serum (FBS) Gibco, USA  
Fetal Bovine Serum (FBS) Sigma, USA  
Fetal Horse Serum (FHS) Gibco, USA  
Gelatine Difco, USA  
Glycine Applichem, D  
L-(+)-Glutamin Acros, B  
Mitomycin C Acros, B  
Penicillin G Potassiumsalt Merck, D  
Penicillin/Streptomycin (P/S) Gibco, USA  
Potassium chloride Sigma, USA  
Potassiumhydrogenphosphate Fluka, CH  
Sodiumhydrongencarbonate LifeTechnologies, USA  
Streptomycin Sigma, USA  
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6.3. General Chemicals and Material 
Acetic acid Merck, D  
Agarose, Biozyme LE Biozyme, D  
APS Biorad, USA  
ß-Mercaptoethanol Loba Feinchemie, AUT  
Bromphenolblue Sigma, USA  
BSA Roth, D  
Chloroform Acros, B  
Coomassie Brilliant Blue R250 Merck, D  
Dabco Sigma, USA  
dNTPs Fermentas, Lithuania  
Dimethylsulfoxid (DMSO) Acros, B  
Dithiothreitol (DTT) Acros, B  
EDTA Acros, B  
EGTA Sigma, USA  
Ethanol Merck, D  
Ethidiumbromide Fluka, CH  
Formaldehyde Merck, D  
Glycerine Merck, D  
Glycerophosphate Merck, D  
Glycin Sigma, USA  
HeBS Promega, USA  
HEPES Merck, D  
Hydrochloric acid (HCl) Acros, B  
Isoamylalcohol Merck, D  
Leupeptin Roche, D  
Lithiumchloride Merck, D  
Lipofectamine 2000 Invitrogen, USA  
Loading Dye Fermentas, Lithuania  
Methanol Merck, D  
Magnesiumchloride
 
Fermentas, Lithuania  
Magnesiumsulfate Fluka, CH  
Milkpowder Fixmilch instant, AUT  
Mowiol 2-88 Hoechst, D  
Nalgene Filter Nalagene Labware, USA  
NaDoc 10% Sigma, USA  
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NP-40 10% Sigma, USA  
PCR-buffer without MgCl2  Fermentas, Lithuania  
PEG6000 and PEG8000 Calbiochem, D  
Pepstatin Roche, D  
Phenylmethansulfonylfluoride (PMSF) Fluka, CH  
Polyacrylamide Merck, D  
Ponceau-S Sigma, USA  
Proteinase Inhibitor Roche, D  
Protein A SepharoseTM CL-4B GE Healthcare, S  
Pyrophosphate Fluka, CH  
Reverse Transcriptase Buffer Invitrogen, USA  
SDS (Sodium Dodecylsulfate) BioRad, USA  
Sodiumazid Acros, B  
Sodiumbicarbonate Sigma, USA  
Sodiumchloride Salinen Austria, AUT  
Sodiumfluorid Donauchemie, AUT  
Sodiumhydrogencarbonate LifeTechnologies, USA  
Sodiumhydrogenphosphate Roth, D  
Sodiumhydroxide Merck, D  
Sodiumthiosulfate  Merck, D  
TEMED Sigma, USA  
Trichloracetic acid Merck, D  
Tris Base LifeTechnologies, USA  
Triton X100 Sigma, USA  
Tween-20 Sigma, USA  
6.4. Kits 
EndoFree Plasmid Maxi Kit   Qiagen, D   
RNeasy Mini Kit   Qiagen, D   
Dual Luciferase Reporter System   Promega, USA   
6.5. Inhibitors and Recombinant Proteins 
Chir99021     Axon, NL  
PD98059      Cayman, USA  
SPARC     Sigma, USA  
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6.6. Plasmids 
6.6.1. Renilla Plasmid 
This pRL-TK vector is an internal control plasmid with a Renilla luciferase reporter 
gene, that is constantly expressed in the cells. Promega #E2241. 
 
 
 
 
 
 
 
 
 
6.6.2. pGL3-Basic (Control) Plasmid 
The pGL3-Basic vector is a control plasmid containing a luciferase gene without a 
promotor. Promega #E1751. 
 
 
 
 
 
 
 
 
 
 
Fig. 43 Promega Renilla Plasmid 
Fig. 44 Promega pGL3-Basic Plasmid 
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6.6.3. pUC Plasmid 
This pUC18 vector is a plasmid without any reporter gene, it is added to keep the DNA 
amout in the different samles constant. 
 
 
 
 
 
 
 
6.6.4. Nkx – luc Plasmid 
The Nkx – luc plasmid is a Promega pGL3b plasmid (#E1751) with an insert of the 
nkx2.5 promoter region in front of a luciferase reporter gene and was obtained by Dr. 
Katherine Yutzey (USA). 
  
 
 
 
 
 
 
 
 
 
 
 
 
From Not I 4651  
nkx2.5 promoter (-3059 to +223) 
Nkx-luc 
8.05 kb 
Fig. 45 Promega pUC18 Plasmid 
Fig. 46 Nkx – luc plasmid: pGL3-Basic vector with nkx2.5 insert 
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Minimal cardiac enhancer 
sequence, 510bp 
6.6.5. Nkx – enhancer – luc Plasmid 
The Nkx – enhancer - luc plasmid is made by Sonja Gawlas, the “minimal cardiac 
enhancer” sequence of the nkx2.5 promoter (published by Ching-Ling, L. et al., 1999) 
is cloned into the Nkx – luc plasmid. 
 
 
 
 
6.6.6. Des – siRNA Plasmid (Clone 4) 
This Desmin – siRNA plasmid contains an antisense sequence for the mouse desmin 
mRNA. The original vector in which the following sequence is clones is the Promega 
pGeneClip hMGFP Vector (Promega #C8790). 
 
 
 
 
 
 
6.6.7. Knock Down Negative Plasmid 
This plasmid is a control plasmid having the same components of the Des – siRNA 
plasmid except that the insert is a sequence that does not have any similarities with the 
desmin mRNA. 
  Cloned sequence: GGAATCTCATTCGATGCATAC 
 
From Not I 4651, nkx2.5 Promoter 
Nkx-enhancer-luc 
8.61 kb 
Cloned sequence: 
GACCATCGCGGCTAAGAACAT 
Fig. 47 Nkx – enhancer - luc
 
Plasmid 
Fig. 48 Desmin – siRNA Plasmid 
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6.6.8. Desmin Plasmid 
This Plasmid contains the desmin cDNA and is used for ectopic expression of Desmin 
in cells. Stratagene #212209. 
 
 
 
 
 
 
6.6.9. TOPFlash Plasmid 
This plasmid carries a luciferase gene under the control of a TCF/LEF binding sites 
containing promoter, which is activated by binding of β-catenin (obtained by 
Hartmund Beug, IMP, Vienna). 
 
 
 
 
 
 
 
 
 
 
 
EcoRI – cDNA DESMIN – BamHI 
Fig. 49 Stratagene PBK-RSV vector with the Desmin cDNA insert 
TCF binding sites were cloned into 
the blunt HindIII site, the CAT 
gene was replaced by the 
Luciferase gene. 
Fig. 50 TOPflash Plasmid: pBLCAT2 plasmid with TCF/LEF
     binding sites and Luciferase reporter gene. 
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6.6.10. pmaxEGFP 
This pmaxGFP plasmid encodes GFP under the control of a strong CMV promoter 
(Cytolmegalovirus promoter). It was provided by Artaker Matthias (Medical 
University of Vienna, Amaxa #VSC-1001). 
  
 
 
 
 
 
6.6.11. pCsx-EGFP-PP-DT 
This vector was obtained from Hidaka (Hidaka et al., 2003). It contains regions 
homologue to the nkx2.5 gene interrupted by an EGFP marker and a puromycin 
resistence selection gene. It can be used for homologue recombination of the nkx2.5 
gene. 
 
 
 
 
 
 
 
  
 
Fig. 51 Amaxa pmaxGFP plasmid 
Fig. 52 pCsx-EGFP-PP-DT plasmid 
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6.7. Primer 
 
  
Primer Name Sequence 5' - 3' Annealing Cycles Product 
(cDNA) 
ANF fwd CGG TGT CCA ACA CAG ATC TG 52,5°C 36x 187 bp 
 
rev TCT CTC AGA GGT GGG TTG AC    
Brachyury fwd ATC AAG GAA GGC TTT AGC AAA TGG G 60°C 36x 159 bp 
 
rev GAA CCT CGG ATT CAC ATC GTG AGA    
Csx fwd CCA TTT GTC ACG TCC TGC ACG ACG 57°c 45X 1924 bp 
 
rev GCT TGC ACT TGT AGC GAC GGT TC    
Desmin fwd TGA CAA CCT GAT AGA CGA 50°C 37x 390 bp 
 
rev TTC TTA TTG GCT GCC TGA    
GAPDH fwd CGT CTT CAC CAC CAT GGA GA 55°C 29x 300 bp 
 
rev CGG CCA TCA CGC CAC AGT TT    
GATA4 fwd GCC TGT ATG TAA TGC CTG CG 53°C 31x 500 bp 
 
rev CCG AGC AGG AAT TTG AAG AGG    
Goosecoid fwd GCA CCA TCT TCA CCG ATG AG 52.7°C 35x 190 bp 
 
rev AGG AGG ATC GCT TCT GTC GT    
Isl1 fwd CGG TGC AAG GAC AAG AAA 49°C 38x 346 bp 
 
rev CAA TAG GAC TGG CTA CCA    
MCEcis Element fwd CGA CGAG GAA ACT CGG AGC TA 54°C 38x 124 bp 
 
rev CTC TGC TGT GTG GCC TTG TA    
Mef2C fwd GGC CAT GGT ACA CCG AGT ACA ACG AGC 66°C 34x 395 bp 
 
rev GGG GAT CCC TGT GTT ACC TGC ACT TGG    
Mesp1 fwd AGA AAC AGC ATC CCA GGA AA 52°C 32x 346 bp 
 
rev GTG CCT GCT TCA TCT TTA    
MHCα fwd GGA AGA GTG AGC GGC GCA TCA AGG 57.7°C 32x 302 bp + 
473 bp 
 
rev CTG CTG GAG AGG TTA TTC CTC G    
MLC1v fwd TCA GGA AGC CCA GGG CAG GC 56°C 38x 86 bp 
 
rev GGA GTC CGA ACC ACT CCT TC    
nkx2.5 fwd CAC CCA CGC CTT TCT CAG TC 57°C 40x 513 bp 
 
rev TGG ACG TGA GCT TCA GCA    
nkx2.5 Promoter1 fwd CTC TGT TTG CTT TCT CGC CA 52.5°C 38x 246 bp 
 
rev ATT GGA GAC AGG CAG CGT TA    
Oct 3/4 fwd GGCAAATCACTGAAGGCTCA 62°C 30x 801 bp 
 
rev CACACCAGTCCACAACATAG    
pCSX fwd GAT GTG GAA TGT GTG CGA GG 55°C 45x 1700 bp 
 
rev TGG ACG TGA GCT TCA GCA C    
T Promoter fwd ATA AAT ACA GCC GAG GTG GCC T 55°C 30x 176 bp 
 
rev CGA CGC TTT CCT TAC AGG AAG    
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6.8. Antibodies 
  
Antibody Company 
cardiac TroponinT Thermo Scientific #MS-295 
Connexin43 Sigma #C6219 
Desmin SigmaAldrich #D1033 
Desmin Abcam #ab8592-500 
GAPDH Millipore, #P04406 
GFP Cell Signalling #2956 
SPARC Santa Cruz, #sc-25574 
α-mouse FITC Dianova #715-095-151 
α-mouse-HRP Pierce, #31430 
α-rabbit-HRP Dianova, #111-035-003 
α-rabbit-TR Dianova #711-075-152 
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6.9. Cell Lines 
6.9.1. Fibroblasts 
- SNL 76/7 Fibroblasts 
The SNL76/7 cell line was established by Allan Bradley. It derives from the 
murine STO fibroblast cell line but additionally has a LIF gene and a neomycin-
resistence gene inserted into the genome (McMahon and Bradley, 1990). 
- C2C12 Fibroblasts 
The C2C12 cell line was produced by Gelen Blau. C2C12 cells are myoblasts 
committed to produce myotubes upon differentiation. 
6.9.2. Embryonic Stem Cells 
- AB2.2 
The AB2.2 cell line is a murine wild type embryonic stem cell line isolated by 
Allan Bradley from the mouse strain 129Sv (Soriano et al., 1991). 
- DC6 
The DC6 cell line is a murine embryonic stem cell line that overexpresses Desmin 
(des+/+ desect). It was produced by Sonja Puz (Puz, 1999). 
- Des-/- 
The Des-/- cell line is a desmin knock out murine embryonic stem cell line 
produced by Georg Weitzer (Milner et al., 1996). 
- Des∆1-48/∆1-48 
The Des∆1-48/∆1-48 cell line is a murine embryonic stem cell line with a mutated 
desmin gene. The first 48 amino acids of the N-terminus are deleted (Hollrigl et al., 
2002). 
- MS15 
The MS15 cells line was established by Martina Stary. It is an embryonic stem cell 
line carrying an EGFP reporter gene and a puromycin resistence gene in one allel 
of the nkx2.5 locus. The reporter and resistence genes are expressed under the 
control of the nkx2.5 promoter. 
6.9.3. Cardiovascular Progenitor Cells 
Twelve different cardiovascular progenitor cell lines were isolated by Georg Weitzer 
and Marc Widner from newborn mice carrying a neomycin resistence gene in one 
allele of the hdac1 locus. The hearts of nine days old mice were cut out, digested with 
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a collagenase/pancreatin solution, co-cultured with embryonic stem cells and feeder 
cells for 10 passages following a 3T3 protocol and selection with G418 resulted in the 
death of murine wild type embryonic stem cells and the isolation of twelve clonal 
cardiovascular progenitor cell lines. Here, the cell lines A5 and H3 were used for 
experiments.  
6.10. Bacteria Strains 
XL-1 blue     Stratagene, USA 
6.11. Material for bacteria culture 
6.11.1. LB Medium 
- 10 g  NaCl 
- 10 g  Tryptone 
- 5 g  yeast extract 
- 1 l  ddH2O 
The three reagents are mixed until the chemicals are dissolved. The LB medium is 
portioned into 500 ml bottles and autoclaved at 100 – 120°C at 1.4 bar for 20 to 30 
minutes. 
6.11.2. LB – plates 
7.5 g agarose (1.5%) are added to a 500 ml bottle of LB – medium. Then, the bottle is 
autoclaved and melted for 30 minutes at 180 Watt in the microwave. The liquid is 
cooled down, antibiotics are added, and the medium is poured into petri dishes. The 
plates are kept at room temperature to solidify and then stored at 4°C. 
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7. Methods 
7.1. Cell Culture 
7.1.1. General Stem Cell Culture Workings 
Glass material for stem cell culture should not encounter with washing-up liquid, 
because already a small amount of it causes death of embryonic stem cells. Therefore it 
is cleaned in a different way than normal laboratory glass ware. 
7.1.1.1. Washing of Glass Bottles for Media and Solutions 
Empty bottles are filled with tap water and a few drops Hypochlorid. They are kept at 
room temperature for about an hour. Then, the bottle is rinsed out with tap water until 
no Hypochlorid is left and it is then washed with milliQ-H2O. It is filled with milliQ-
H2O, kept at room temperature for 24 hours, dried and finally autoclaved at 120°C and 1 
bar. 
7.1.1.2. Washing of Pipettes 
After usage, the glass pipettes are stored in Hypochlorid containers. When they are full, 
the pipettes are transferred to another container and are rinsed with tap water for at least 
4 hours. The pipettes are then stored in milliQ-H2O over night and afterwards dried in a 
drying oven at 60°C. A piece of cotton is plugged into each pipet, they are put into the 
pipet boxes and are baked at 180°C for 8 hours. 
7.1.2. Buffer and Media for Cell Culture 
10x PBS (Phosphate Buffered Saline) stock solution 
- 1.37 M  NaCl 
- 14.7 mM  KCl 
- 78.1 mM  Na2HPO4 x 7H2O 
- 26.8 mM  KH2PO4 
- Saturated Na2HPO4 is added to a final pH of 7.2. 
- The solution is sterile filtered (Nalagene Filter, 0.22 µm pore width). 
100x GPS (Glutamine-Penecillin-Streptomycin) 
- 4.25 g NaCl 
- 1.5 g Penicillin 
- 2.5 g Streptomycin 
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- 14.6 g L-(+)-Glutamine 
- MilliQ-H2O is added to a final volume of 500 ml. 
- The solution is stored at -20°C and then kept at 4°C after thawing. 
100x β-Mercaptoethanol (10-2M) 
- 200 ml 1x PBS 
- 144 µl β-Mercaptoethanol (14 M) 
- The solution is sterile filtered. 
- The solution is stored at -20°C and then kept at 4°C after thawing. 
Trypsin 
- 3.5 g  NaCl 
- 0.5 g D-Glucose 
- 0.09 g Na2HPO4 x 7H2O 
- 0.185 g KCl 
- 0.12 g KH2PO4 
- 0.2 g EDTA 
- 1.25 g Trypsin (Gibco) 
- 1.5 g Tris Base 
- MilliQ-H2O is added to a final volume of 500 ml. 
- Concentrated HCl is added to a final pH of 7.6.  
- The solution is stored at -20°C and then kept at 4°C after thawing. 
1% Gelatine Stock Solution 
 10 g Gelatine (Difco) are soluted in 1 l milliQ-H2O. The solution is sterile 
 filtered. 
 DMEM (Dulbecco’s Modified Eagle’s Medium) 
A 5 l Erlenmeyer Flask is filled with 4.5 l milliQ-H2O. Half a DMEM can 
(Gibco, +4500 mg/l Glucose, -NaHCO3, -Pyruvate #52100-039) is added and 
dissolved. 18.5 g NaHCO3 are added. Concentrated HCl added to a final pH of 
7.4. MilliQ-H2O is added to a final volume of 5 l and the medium is sterile 
filtered into cell culture falsks. 
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 Freezing Medium 
- 60% DMEM 
- 20% Fetal Bovine Serum (company depends on cell line, use the one 
they are normally cultured with) 
- 20% DMSO (Dimethylsulfoxid) 
 
 PBS/Collagenase/Pancreatin Solution 
- 10 ml 1x PBS 
- 5 mg Collagenase (Worthington) 
- 6 mg Pancreatin (Gibco) 
 
7.1.3. Growing Media 
  
 Medium for Fibroblasts (M10Gi) 
- 89%  DMEM 
- 10%  Fetal Bovine Serum (Gibco) 
- 1%  GPS (Glutamine-Penicillin-Streptomycin) 
 
 Medium for embryonic stem cells and cardiovascular progenitor cells (M15Hi) 
- 83 %  DMEM 
- 15%  Fetal Bovine Serum (HyClone) 
- 1%  GPS (Glutamine-Penicillin-Streptomycin) 
- 1%  β-Mercaptoethanol 
 
 Medium for Embryoid and Cardiac Bodies (M15Si) 
- 83%  DMEM 
- 15%  Fetal Bovine Serum (Sigma) 
- 1%  GPS (Glutamine-Penicillin-Streptomycin) 
- 1%  β-Mercaptoethanol 
Medium for primary Cardiomyocytes (pCMC) 
- 59%  DMEM 
- 20%  Fetal Bovine Serum (Gibco) 
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- 20%  Horse Serum (Gibco) 
- 1%  GPS 
 
7.1.4. Gelation of Tissue Plates 
0.1% Gelatinesolution is pipetted on the tissue plates so that the bottom is covered 
with the solution. It is kept at room temperature for two hours and then the solution is 
aspirated. 
7.1.5. Fibroblasts 
7.1.5.1. Culture of SNL76/7 Fibroblasts 
Embryonic stem cells grow on so called feeder cells, a layer of fibroblast cells which 
produce LIF and therefore keep the embryonic stem cells in an undifferentiated state. 
The SNL76/7 cell line derives from the STO fibroblast cell line but additionally has a 
LIF gene inserted into the genome. The cells are cultured on 0.1% gelled 10 cm cell 
culture plates at 37°C and 5% CO2. They are fed with M10Gi as soon as the colour of 
the medium changes and when they reach confluence, they are split in an up to 1:8 
ratio. 
7.1.5.2. Culture of C2C12 Fibroblasts 
The fibroblasts are incubated at 37°C and 5% CO2 in 10 cm tissue plates and are split 
every second or third day in a 1:8 ratio. 
7.1.5.3. Thawing of Fibroblasts 
The cells are stored in 2 ml Kryotubes in liquid nitrogen at -180°C. 
The tubes are taken out of the liquid nitrogen. The cells are thawed in the 37°C water 
bath and transferred to a 15 ml falcon. M10Gi medium (6 ml medium/1 ml cell 
suspension) is added drop by drop, after each drop the falcon is gently shaken. The 
cells are then centrifuged for 7 minutes, 1000 rpm at room temperature. The medium 
is aspirated and the cells are resuspended in 4 ml fresh M10Gi. The cells are 
transferred to a (gelled) 10 cm culture plate, the falcon is rewashed with 4 ml M10Gi, 
which are also transferred to the culture plate. The cells are dispersed by moving the 
plate in a shape of an eight and are then incubated at 37°C.  
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7.1.5.4. Splitting of Fibroblasts 
The medium in the plate is aspirated and the cells are washed with 1x PBS. The PBS is 
apirated and 1 ml Trypsin is pipetted to the cells. The plate is incubated at 37°C for 5 
minutes. The cells are resuspended in 7 ml fresh M10Gi medium and 1 ml of this 
suspension is transferred to a new (gelled) 10 cm plate (1:8 ratio). 8 ml fresh M10Gi 
are added and the plate is incubated at 37°C. 
7.1.5.5. Freezing of Fibroblasts 
The medium is aspirated and the cells are washed with 1x PBS. 700 µl Trypsin are 
added to the cells and the plate is incubated for 10 minutes at 37°C. The cells are 
resuspended in 2 ml M10Gi and transferred to a 15 ml falcon. 2.7 ml freezing medium 
are added drop by drop, after each drop the falcon is gently shaken. The cell 
suspension is apportioned to three Kryotubes, the tubes are put into a Styrofoam box 
which is placed into the -80°C freezer for at least 24 hours and then the tubes are 
stored in liquid nitrogen. 
7.1.5.6. Production of Feeder Cells 
One 10 cm culture plate with confluent SNL76/7 cells is enough for about two 24 well 
plates. In the course of producing feeder cells, the SNL76/7 cells have to get 
mitotically inactivated so that they do not divide anymore but still produce all factors 
needed for self-renewal. 
The medium of the 10 cm culture plate is aspirated except 4 ml. 80 µl Mitomycin C are 
added drop by drop and the plate is incubated at 37°C for 3 – 4 hours. The medium is 
aspirated and the cells are washed twice with 1x PBS. 1 ml Trypsin is pipetted to the 
cells and they are incubated at 37°C for 10 minutes. The cells are resuspended in 5 ml 
M10Gi and transferred to a sterile 15 ml falcon. The plate is rewashed with 10 ml 
M10Gi, which are also pipetted to the falcon. The falcon is centrifuged for 7 minutes, 
1000 rpm at room temperature and the supernatant is aspirated. The pellet is 
resuspended in 10 ml M10Gi and the cell count is determined. The cells are diluted to 
a concentration of 3.5 x 105 cells/ml and seeded to gelled 24 well plates, 0.5 ml per 
well. The plates are incubated at 37°C and can be used on the next day when the cells 
adhere to the plate. 
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7.1.6. Embryonic Stem Cells (ESCs) and Cardiovascular Progenitor Cells 
(CVPCs) 
7.1.6.1. Culture of Embryonic Stem Cells and Cardiovascular Progenitor Cells 
The cells are incubated at 37°C and 5% CO2 in 24 well plates, are fed every 24 hours 
with M15Hi and are split at approximatly 90% confluence in a 1:3 ratio. 
7.1.6.2. Thawing of Embryonic Stem Cells and Cardiovascular Progenitor Cells 
The cells are stored in 2 ml Kryotubes in liquid nitrogen at -180°C. 
Two hours before thawing, the feeder cells on which the cells will grow are fed with 2 
ml M15Hi. The tubes are taken out of the liquid nitrogen. The cells are thawed in the 
37°C water bath and transferred to a 15 ml falcon. M10Gi medium (approximately 6 
ml medium/1 ml cell suspension) is added drop by drop, after each drop the falcon is 
gently shaken. The cells are then centrifuged for 7 minutes, 1000 rpm at room 
temperature. The medium is aspirated and the cells are resuspended in 1 ml medium of 
the prefed feeder cells. They are then transferred to the feeder well. The cells are 
incubated at 37°C. 
7.1.6.3. Splitting of Embryonic Stem Cells and Cardiovascular Progenitor Cells 
Two hours before splitting, the feeders on which the cells will grow are fed with 2 ml 
M15Hi and the embryonic stem cells that will be split are fed with 1 ml M15Hi. The 
medium in the well is aspirated and the cells are washed with 1x PBS. The PBS is 
apirated and 200 µl Trypsin are pipetted to the cells. The plate is incubated at 37°C for 
15 minutes. The cells are resuspended in 1 ml medium of the prefed feeder cells and 
400 µl (if splitting ratio is 1:3) of this suspension are transferred to the feeder well. The 
plate is incubated at 37°C. 
7.1.6.4. Freezing of Embryonic Stem Cells and Cardiovascular Progenitor Cells 
Two hours before freezing, the embryonic stem cells are fed with 1 ml M15Hi. The 
medium is aspirated and the cells are washed with 1x PBS. 200 µl Trypsin are added 
to the cells and the plate is incubated for 15 minutes at 37°C. The cells are 
resuspended in 800 µl M15Hi. 1 ml freezing medium is added drop by drop directly to 
the well, after each drop the plate is gently shaken. The cell suspension is apportioned 
to two Kryotubes, the tubes are put into a Styrofoam box which is placed into the -
80°C freezer for at least 24 hours and then the tubes are put into the liquid nitrogen. 
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7.1.7. Embryoid Bodies and Cardiac Bodies 
7.1.7.1. Production of Embryoid Bodies and Cardiac Bodies 
One day before embryoid bodies (EBs) and cardiac bodies (CBs) are made, the 
embryonic stem cells and cardiovascular progenitor cells  that will be used for the EBs 
and CBs are split in a 1:2 ratio so that the cells are in an optimal condition. 
Two hours before starting, the cells are fed with 1 ml M15Hi. The medium is then 
aspirated and the cells are washed with 1x PBS. 200 µl Trypsin are added to the cells 
and the plate is incubated for 15 – 20 minutes at 37°C. The cells are resuspended in 
800 µl M15Si and pipetted to a gelled 6 well plate, and the original well is rewashed 
with 1 ml medium. The plate is incubated for 1 hour at 37°C so that the fibroblasts 
adhere to the gelled plate but the embryonic stem cells do not. The supernatant is 
pipetted to a 50 ml falcon and is expanded to 10 ml with M15Si. The cell count is 
determined. The cells are diluted to a concetration of 4 x 104 cells/ml (for EBs) and 
4.5x104 cells/ml (for CBs) and measured again until the correct cell count is detected in 
the solution. Sterile bacteria plates are filled with autoclaved milliQ-H2O. 20 µl drops 
are pipetted to the lid of the bacteria plates (approximately 100 drops per lid). The lid 
is put on the plate containing the water and the plate is incubated at 37°C. The day, on 
which the embryoid and cardiac bodies are made is day 0. On day 4.5 (EBs) and day 
4.7 (CBs) the drops in the lid are rinsed with about 8 ml M15Si medium into a gelled 
10 cm cell culture plate and the embryoid and cardiac bodies are dispered by rocking 
to two different directions. The plate is incubated at 37°C. 
7.1.7.2. Culture of Embryoid Bodies and Cardiac Bodies 
Embryoid and cardiac bodies are fed every third day, however a part of the old 
medium is kept and fresh medium is added to the old one.  
On day 7 and day 10, 3 ml old medium are kept in the plate and 8 ml fresh M15Si are 
added. 
On day 13, day 16, day 19 and day 22, 4 ml old medium are kept in the plate and 10 ml 
fresh M15Si are added. 
From day 25, 5 ml old medium are kept in the plate and 12 ml fresh M15Si are added. 
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7.1.7.3. Trypsinisation of Embryoid and Cardiac Bodies 
The plates are washed twice with 1x PBS. 2 ml of Trypsin/Collagenase/Pancreatin (for 
20 ml: 20 ml Trypsin, 10 mg Collagenase, 12 mg Pancreatin) are added to each plate 
and they are incubated at 37°C for 20 minutes. The cells are resuspended in 8 ml 
M15Si and pooled into a 50 ml falcon. The falcon is centrifuged for 10 seconds, the 
supernatant is collected, the pellet is resuspended in 2 ml 
Trypsin/Collagenase/Pancreatin and incubated at 37°C for 10 minutes. The cells are 
resuspended in 8 ml M15Si, transferred to a 50 ml falcon. The falcon is centrifuged for 
10 seconds, the supernatant is pooled, the pellet is resuspended in 1 ml 
Trypsin/Collagenase/Pancreatin and incubated at 37°C for 7 minutes. The cells are 
resuspended in 5 ml M15Si and pooled with the previous supernatants. After 
centrifugation for 5 minutes at 1000 rpm, the pellet can be resuspended in the desired 
solution. 
 
7.2. Isolation of primary Cardiomyocytes 
The hearts of newborn mice are cut out and placed into a tube containing 1x PBS (up 
to three hearts per tube). The PBS is removed and the hearts are cut into small pieces. 
1 ml 1x PBS is added and the tube is centrifuged for 2 minutes at 1200 rpm. The PBS 
is aspirated and 1 ml PBS/Collagenase/Pancreatin solution is added. The solution is 
incubated at 37°C for 7 minutes. It is then centrifuged for 2 minutes at 1200 rpm. The 
supernatant is removed. 1 ml PBS/Collagenase/Pancreatin solution is added and 
incubated at 37°C for 3 minutes. The mixture is centrifuged for 2 minutes at 1200 rpm 
and the supernatant is removed. The cells are resuspended in pCMC medium and 
transferred to a 1% gelatine coated 6 cm plate. The cells are incubated at 37°C for 60 
minutes. The supernatant is transferred to a new 1% gelatine coated plate which is 
incubated at 37°C. 
 
7.3. DNA Isolation 
DNA is isolated of one confluent 24 well. 
The cells are trypsinised, resuspended in 1x PBS and transferred into a Kloesch tube. 
The tube is centrifuged for 10 minutes at 1200 rpm and 4°C. The supernatant is 
aspirated, the pellet resuspended in 1 ml 1x PBS and centrifuged for 10 minutes at 
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1200 rpm and 4°C. The supernatant is aspirated, the pellet is resuspended in 800 µl 
PK-Buffer and incubated at 50°C and 700 rpm over night. On the next day, the 
solution is partitioned into two tubes and 400 µl Phenol are added to each tube. The 
solution is mixed by inverting several times and then centrifuged at 14000 rpm for 10 
minutes. The upper phase is transferred into a new Kloesch tube and again 400 µl 
Phenol are added, inverted and centrifuged for 10 minutes at 14000 rpm. The upper 
phase is again transferred into a new tube and 580 µl Cloroform + 20 µl 
Isoamylalcohol are added, the tubes are inverted and then centrifuged for 10 minutes at 
14000 rpm. The upper phase is transferred into a new tube. 1 ml 96% EtOH and 50 µl 
3M NaOAc are added and the tubes are kept at -80°C for 1.5 hours. They are then 
centrifuged at 14000 rpm for 15 minutes at 4°C to pellet the precipitated DNA. The 
supernatant is aspirated and the pellet is washed with 500 µl 70% EtOH. The tube is 
centrifuged for 10 minutes at 14000 rpm and 4°C. The supernatant is aspirated and the 
pellet is dried. 40 µl milliQ-H2O are added and the tubes are incubated at 37°C and 
700 rpm for 30 minutes. The content of the two tubes is pooled and the DNA is stored 
at -20°C. 
PK Buffer: 
 0.5 ml  1 M Tris pH 8 
 20 µl  0.5 M EDTA pH 8 
 100 µl  10% SDS 
 200 µl  Proteinase K 10 mg/ml 
 9.18 ml dH2O 
 
7.4. PCR 
Master Mix 
 38.75 µl  milliH2O 
 5 µl  10x Taq Buffer (Fermentas #EP0402) 
 3 µl  25 mM MgCl2 (Fermentas #EP0402) 
 1 µl  10 mM dNTPs (Fermentas #R0192) 
 0.5 µl  Primer forward (Vienna BioTec) 
 0.5 µl  Primer reverse (Vienna BioTec) 
 0.25 µl  Taq Polymerase (Fermentas #E0402) 
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The master mix is pipetted into PCR tubes (Kloesch) and 1-2 µl of sample DNA are 
added. The tubes are placed into a Biometra T-Personal PCR machine. 
PCR Conditions 
1. 94°C  60 seconds 
2. 94°C  45 seconds 
3. Annealing  45 seconds (annealing temperature depends on primers) 
4. 72°C  60 seconds  back to step 2 for 28-39 cycles 
5. 72°C  240 seconds 
6. 4°C  
 
7.5. mRNA Isolation and Reverse Transcription 
To isolate mRNA from cells, the Quiagen RNeasy Mini Kit is used. 
The medium of the cells of interest is aspirated and the cells are washed with 1x PBS. 
The PBS is aspirated and 1 ml 1x PBS is added. The cells are scraped off, resuspended 
and transferred to 15 ml falcon tubes. They are centrifuged for 5 minutes, 1000 rpm at 
room temperature and the pellet is resuspended in 1 ml 1x PBS. The mixture is 
transferred into a tube, centrifuged for 5 minutes at 14000 rpm and 4°C and the 
supernatant is aspirated. β-Mercaptoethanol is added to RTL buffer (1:100). 606 µl of 
this solution are added to each tube, the pellet is resuspended and pipetted into a 
Shredder Column. It is centrifuged for 2 minutes, 13000 rpm at room temperature. The 
column is discarded and 606 µl of 70% EtOH (RNase free) are pipetted to the solution, 
mixed and 600 µl of this mixture are pipetted to a RNeasy column. The column is 
centrifuged for 15 seconds at full speed. The flow through is discarded and the other 
600 µl of the mixture are pipetted to the RNeasy column. The column is again 
centrifuged for 15 seconds at full speed and the flow through is discarded. 700 µl RW1 
are added followed by 15 seconds full speed centrifugation and flow through removal. 
This step is repeated with 500 µl RPE. Then 500 µl RPE are added, the column is 
centrifuged for 1 minute at 13000 rpm, and the column is put into a new 1.5 ml tube. 
30 µl RNase-free water are added and the tubes are centrifuged for 1 minute, 13000 
rpm at room temperature. The column is discarded and the DNA is digested by adding 
3.75 µl DNase buffer (Fermentas) and 3.75 µl DNase I (Fermentas). After incubation 
for 30 minutes at 37°C, 3.75 µl EDTA (Fermentas) are added to stop the DNA 
digestion and the tubes are incubated at 65°C for 30 minutes. The samples are kept on 
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ice and a PCR with GAPDH Primers is made with the samples as templates to detect 
whether there is still some genomic DNA left in the samples. During running the PCR 
the samples are frozen at -80°C. The PCR products are loaded on a 1.5% agarose gel 
which is run at 130 Volt for about 1 hour. The gel is then put into an Ethidiumbromid 
bath for about 20 minutes and afterwards the DNA bands are detected under an UV 
light. 
If there is no band visible, the protocol can be continued and the RNA can be reversely 
transcribed. 
1 µl oligo-d(T) is added to each sample and they are incubated at 70°C for 10 minutes. 
The samples are then kept on ice for 3 minutes and centrifuged for 30 seconds, 13000 
rpm at room temperature. 18.5 µl RT (reverse transcription) Mix are added to each 
sample. The samples are incubated for 2 minutes at 42°C and 1 µl Reverse 
Transcriptase (Fermentas) is added to each sample. They are incubated at 42°C for 50 
minutes. They are further incubated at 70°C for 15 minutes. Then, the samples are kept 
on ice for 5 minutes and centrifuged for 2 minutes, 13000 rpm. The samples can be 
stored at -20°C.  
The first thing that has to be tested is, if there is the same amount of cDNA in each 
sample. Therefore a PCR is made with Primers for the house-keeping gene GAPDH. If 
all GAPDH bands on the gel have the same intensity, PCRs with primers for the 
sequence of interest can be made.  
1x RT Mix 
 10 µl  5x FS Buffer 
 0.5 µl  0.1 M DTT 
 1.5 µl  RNase Inhibitor 
 2 µl  10 mM dNTPs 
 
7.6. Chromatin Immunopäzipitation (ChIP) 
With this method, it is possible to detect protein-DNA interaction. 
Here, the interaction of the Protein Desmin with the nkx2.5 promoter region should 
have been detected. 
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300 µl Formaldehyd/10 ml medium are added to the 10 cm plates on which cells of 
interest grow (to X-link proteins and DNA). The plate is incubated for 40 minutes at 
room temperature. 500 µl Glycine/10 ml medium are added and the plate is shaken for 
5 minutes (to stop X-linking). The supernatant is aspirated and the cells are washed 
with ice cold 1x PBS. 1 ml ice cold 1x PBS is added and the cells are scraped off and 
transferred to a falcon tube. They are centrifuged for 5 minutes at 1200 rpm and 4°C. 
The supernatant is aspirated and the pellet is washed with 5 ml WASH I. Therefore, 
the pellet is resuspended in 1 ml WASH I, then 4 ml WASH I are added, the falcon is 
shaken and kept on ice for 10 minutes. This is followed by centrifugation for 5 
minutes, 1200 rpm, 4°C. The washing step is repeated with WASH II. The pellet is 
resuspended in 1 ml Lysis Buffer. The solution is transferred to a 2 ml Kloesch tube 
and stored at 4°C over night.  
The cells are sonicated so that they burst and that the DNA is fractured into pieces of 
600 – 800 bp length. The Kloesch tube is kept on ice and the sonication is repeated 16 
times with 90% Dot Cycles and 45% Output for 15 seconds. After each sonication the 
tubes are kept on ice for 35 seconds. The cell fragments are centrifuged for 10 minutes, 
full speed, 4°C. The supernatant is collected and the OD at 280 nm is measured with a 
NanoDrop machine. Therefore 2 µl of sample are soluted in 98 µl ddH2O and OD280 is 
measured. The samples are then brought to an eqal volume depending on their protein 
concentration. If OD280 is 0.1  100 µl sample are used. Lysis Buffer to a final volume 
of 140 µl is added, 260 µl Elution Buffer and 20µl 4M NaCl are added. The tubes are 
incubated at 65°C and 300 rpm over night (in order to reverse the x-link). 
The proteins are degraded by adding 8 µl 0.5 M EDTA, 16 µl 1 M Tris pH 6.5 and 2 µl 
Proteinase K (20 mg/ml). The samples are incubated for 1 hour at 55°C and 400 rpm. 
Under the flue, 600 µl Phenol are added to the samples, the lid is sealed with Parafilm, 
the samples are vortexed and centrifuged for 2 minutes, full speed at room 
temperature. The upper phase is collected in a new Kloesch tube and the procedure is 
repeated with Chloroformisopropanol (24:1). The supernatant is collected in a new 
Kloesch tube and 800 µl 96% EtOH (-20°C), 12 µl 3 M NaOAc and 1 µl Glycogen are 
added. The samples are kept at –20°C for at least 2.5 hours. This is followed by 
centrifugation at 4°C for 25 minutes at full speed. 800 µl 70% EtOH are added to wash 
the pellet. It is centrifuged for 10 minutes at 4°C and full speed. The supernatant is 
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aspirated and the pellet is air-dryed. 100 µl ddH2O and 1 µl RNAse are added and 
incubated at 37°C for half an hour.  
These samples are used as the Inputs (IN). The length of the DNA fragments is 
checked. Therefore 20 µl of the samples are loaded on a 0.8% agarose gel. 
The samples for the Immunoprecipitation are then made. 
The Protein A beads have to be prepeared before usage. Therefore, 2-3 spatula tips of 
Protein A beads are put into a Kloesch tube and 1 ml TE Buffer is added. The beads 
are incubated for 30 minutes at room temperature. They are then centrifuged for 3 
minutes, 1000 rpm at room temperature. Afterwards, they are washed three times with 
TE. The amount of beads is estimated and the same amount of blocking solution is 
added. The beads are shaken at 4°C for 30 minutes. Then, the tube is centrifuged for 3 
minutes at 1000 rpm. The supernatant is discarded, the pellet is washed with TE, 
centrifuged and the supernatant is again discarded. The amount of beads is estimated 
and the same amount TE Buffer is added. 
The sonicated samples are brought to an eqal volume depending on their 
concentration. If OD280 is 0.1  100 µl sample are used. Lysis Buffer to a final volume 
of 140 µl is added and 860 µl Dilution Buffer are pipetted to the solution. 25 µl Protein 
A beads are added to the samples and the tubes are shaken at 4°C for one hour to pre-
clear the chromatin. The pre-cleared chromatin is then centrifuged for 5 minutes, 1200 
rpm at 4°C. The supernatant is transferred to a new Kloesch tube, 2.5 µl α-Desmin 
antibody are added and the tubes are shaken at 4°C over night. 35 µl Protein A beads 
are added and the tubes are shaken at 4°C for 4 hours. The tubes are centrifuged, the 
supernatant is discarded and 900 µl of RIPA buffer (to get rid of unspecific binding) is 
added to the immune-complexes. The tubes are shaken for 10 minutes at 4°C and then 
centrifuged for 5 minutes, 1200 rpm at 4°C. The washing step is repeated with HI Salt 
buffer (to get rid of unspecific binding) and with LiCl buffer (to get rid of RNA 
crosslinked to complexes). The washing step is finally repeated twice with TE Buffer 
(to neutralise). After removal of the supernatant, 400 µl Elution Buffer are added to the 
beads. The complexes are shaken for 5 minutes, 300 rpm at room temperature. 20 µl 4 
M NaCl are added and the tubes are gently shaken at 300 rpm at 65°C over night to 
reverse the X-link. The proteins are degraded by adding 8 µl 0.5 M EDTA, 16 µl 1 M 
Tris pH 6.5 and 2 µl Proteinase K (20mg/ml) and incubating them for 1 hour at 55°C 
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and 400 rpm. Under the flue, 600 µl Phenol are added to the samples, the lid is sealed 
with Parafilm, the samples are vortexed and centrifuged for 2 minutes, full speed at 
room temperature. The upper phase is collected in a new Kloesch tube and the 
procedure is repeated with Chloroformisopropanol (24:1). The supernatant is collected 
in a new tube and 800 µl 96% EtOH (-20°C), 12 µl 3 M NaOAc and 1 µl Glycogen are 
added. The samples are kept at –20°C for at least 2.5 hours. This is followed by 
centrifugation at 4°C for 25 minutes at full speed. 800 µl 70% EtOH are added to wash 
the pellet. It is centrifuged for 10 minutes at 4°C and full speed. The supernatant is 
aspirated and the pellet is air-dryed. 100 µl ddH2O and 1 µl RNAse are added and 
incubated at 37°C for half an hour. 
These samples are used as the Immunoprecipitation (IP) samples. 
For the following PCRs, 2 µl of the INPUT samples and 10 µl of the 
IMMUNOPRECIPITATION samples respectivly are used as template DNAs. 
PCR Master Mix (1x): 
 37.75 µl milliH2O 
 5 µl  10x Taq Buffer (Fermentas #EP0402) 
 4 µl  25 mM MgCl2 (Fermentas #EP0402) 
 1 µl  10 mM dNTPs (Fermentas #R0192) 
 0.5 µl  Primer forward (Vienna BioTec) 
 0.5 µl  Primer reverse (Vienna BioTec) 
 0.25 µl  Taq Polymerase (Fermentas #EP0402) 
 
PCR conditions: 
1. 95°C 4 minutes 
2. Annealing 90 seconds  (Annealing temperature depends on Primer ) 
3. 72°C 90 seconds 
4. 95°C 60 seconds  
5. Annealing 30 seconds  
6. 72°C 45 seconds  back to step 4 
7. 72°C 90 seconds 
8. 4°C  
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The PCR products are loaded on a 1.8% agarose gel (the agarose concentration 
depends on the length of the produced fragment, the smaller the product, the higher the 
agarose concentration should be in order to get a good separation), which is run at 130 
V for about 1.5 hours. The gel is then put into an Ethidiumbromid bath for about 20 
minutes and afterwards the DNA bands are detected under an UV light. 
Buffer for Chromatin Immunoprecipitation: 
WASH I 
 10 ml  10% Triton x-100 
 8 ml  0.5 M EDTA 
 400 µl  1 M Hepes 
 ddH2O ad 400 ml 
 +200 µl/10 ml Proteinase Inhibitor (add immeadiatly before use) 
 +10 µl/10 ml PMSF (add immeadiatly before use) 
WASH II 
 20 ml  4 M NaCl 
 800 µl  0.5 M EDTA 
 400 µl  0.5 M EGTA 
 4 ml  1 M Hepes 
 ddH2O ad 400 ml 
 +200 µl/10 ml Proteinase Inhibitor (add immeadiatly before use) 
 +10 µl/10 ml PMSF (add immeadiatly before use) 
Lysis Buffer 
 100 µl  10% SDS 
 20 µl  0.5 M EDTA 
 50 µl  1 M Tris pH 8.1 
 20 µl Proteinase Inhibitor 
 1 µl PMSF 
 ddH2O ad 1 ml 
Elution Buffer 
 200 µl  10% SDS 
 100 µl  1 M NaHCO3 
 10 µl  1 M DTT (Dithiothreitol) 
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 ddH2O ad 1 ml 
TE Buffer 
 4 ml  1 M Tris pH 8 
 800 µl  0.5 M EDTA 
 ddH2O ad 400 ml 
 The solution is autoclaved. 
Blocking Solution (for 100 µl beads) 
 2 µl  Herring Sperm 
 10 µl  BSA (10 mg/ml) 
 5 µl  NaAcid 2% 
 84 µl  TE 
Dilution Buffer 
 800 µl  10% SDS 
 44 ml  10% Triton x-100 
 960 µl  0.5 M EDTA 
 6.68 ml  1 M Tris pH 8,1 
 16.7 ml  4 M NaCl 
 ddH2O ad 400 ml 
RIPA Buffer 
 15 ml  4 M NaCl 
 20 ml  1 M Tris pH 8 
 4 ml  10% SDS 
 20 ml  10 M NaDoc 
 40 ml  10% NP-40 
 ddH2O ad 400 ml 
HI Salt Buffer 
 50 ml  4 M NaCl 
 20 ml  1 M Tris pH 8 
 4 ml  10% SDS 
 40 ml  10% NP-40 
 ddH2O ad 400 ml 
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LiCl Buffer 
 100 ml  1 M LiCl 
 20 ml  1 M Tris pH 8 
 20 ml  10% NaDoc 
 40 ml  10% NP-40 
 ddH2O ad 400 ml 
Elution Buffer 
 1 ml  10% SDS 
 0.5 ml  1 M NaHCO3 
 50 µl  1 M DTT 
 ddH2O ad 5 ml 
 
7.7. Cloning Systems 
7.7.1. Production of competent E.Coli 
A colony of E.Coli XL1-blue is picked, transferred to a flask containing 5 ml LB 
medium, and is incubated over night at 37°C. The bacteria culture is diluted with 45 ml 
LB medium in a 250 ml flask and is incubated until a density of OD600 = 0.3 – 0.6 is 
reached (about 2 hours). The culture is centrifuged at 4°C for 10 minutes and 1000 g. 
The supernatant is aspirated and the pellet is resuspended in 5 ml TSB. The solution is 
kept on ice for 10 minutes and then aliquoted in pre-cooled Kloesch tubes. The 
bacteria are shock-frozen in liquid nitrogen and then stored at -80°C. 
TSB (sterile filtered) 
 10% PEG6000 or PEG8000 
 5% DMSO 
 10 mM MgCl2 x 6 H2O 
 10 mM MgSO4 x 7 H2O 
 LB medium 
7.7.2. Transformation of competent E.Coli 
2 µl of Plasmid DNA are pipetted to 500 µl of competent E.Coli XL1-blue and are 
mixed by inverting the tube. The suspension is kept on ice for 30 minutes, transferred 
to 42°C for 30 seconds and immediately put on ice. 250 µl LB medium are added and 
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the mixture is shaken (300 rpm) at 37°C for 60 minutes. Antibiotic selective LB-agar 
plates are prewarmed and 10 µl and 30 µl of the bacteria solution are spread to the 
plate and incubated over night at 37°C. The next day single colonies can be picked. 
7.7.3. Glycerol Stocks of E.Coli 
Glycerolstocks are used for long-term storage of bacteria containing a specific 
plasmid. 
A single colonie of competent E.Coli transformed with the plasmid of interest is 
picked and transferred into a cuvette tube containing 2 – 5 ml antibiotic selective 
medium. The bacteria are incubated and shaken over night at 37°C. The next day, 850 
µl of the overnight culture are mixed with 150 µl sterile 87% Glycerol and are 
transferred to a cryotube. The bacteria are shock-frozen in liquid nitrogen and then 
frozen at -80°C. 
7.7.4. Plasmid Preparation 
To transfect cells with plasmids, they have to be extracted from bacteria that were 
transformed with the plasmid of interest. For the Plasmid Preparation, the Qiagen 
MaxiPrep Kit is used. 
A piece of a glycerol stock is transferred to an antibiotic-selective LB-agar plate and 
incubated at 37°C over night. The next day, a single colony is picked and transferred 
into a tube containing 3 ml antibiotic selective LB medium. The tube is shaken at 37°C 
for about 4 hours and then the content of the tube is transferred into a 1 l flask 
containing 150 ml antibiotic selective LB medium. The flask is incubated and shaken 
at 37°C over night. The overnight culture is centrifuged for 15 minutes at 4°C and 
8500 rpm. The pellet is resuspended in 10 ml Buffer P1 and transferred to a 50 ml 
falcon. 10 ml Buffer P2 are added, the tube is inverted and kept at room temperature 
for 5 minutes. 10 ml Buffer P3 are added, the tube is inverted 5 – 6 times and kept at 
room temperature for 10 minutes. It is then centrifuged for 5 minutes at 8000 rpm and 
the supernatant is transferred to a Qiagen Cartridge. The content is pushed through the 
cartridge into a new falcon. 2.5 ml ER buffer are added, the tube is inverted about 10 
times and kept on ice for 30 minutes. A Qiagen-tip 500 is filled with 10 ml QBT and 
the column is emptied by gravity flow. Then the filtered lysate is applied to the 
Quiagen-tip and left until it flew through the tip. The tip is washed two times with 30 
ml Buffer QC. Then 15 ml Buffer QN are added to elute the DNA into a new flask. 
10.5 ml isopropanol are added, mixed and centrifuged for 30 minutes at 15000 rpm 
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and 4°C. The supernatant is discarded, 5 ml 70% Ethanol are added and the tube is 
again centrifuged for 10 minutes at 4°C and 15000 rpm. The supernatant is aspirated, 
the pellet is dried and then dissolved in 600 µl TE-buffer. The DNA concentration is 
measured on a NanoDrop machine and the Plasmid DNA is stored at -20°C. 
 
7.8. Transfection 
7.8.1. Transfection of Fibroblasts 
7.8.1.1. Calcium Phosphate Transfection 
1.2 x 105 C2C12 fibroblast cells are seeded to each well of a gelled (0.1% gelatine) 6 
well plate. The plate is incubated over night at 37°C. On the next day, the medium is 
aspirated and 2.5 ml fresh M10Gi medium are added to each well. The plate is 
incubated for about 3 hours. For each well one 2 ml Kloesch tube is prepared with 300 
µl HeBS buffer. For each well one 1.5 ml Kloesch tube is prepared with 12 µg of 
Plasmid-DNA dissolved in milliQ-H2O to a total volume of 263 µl and 37 µl 2 M 
CaCl2. The HeBS tubes are put on a vortex machine and the 300 µl DNA solution is 
pipetted to the HeBS buffer. The mixture is vortexed for 30 more seconds and is then 
kept on room temperature for 30 minutes. The DNA solutions are then pipetted to the 
wells and the plate is incubated at 37°C. About 24 hours after the transfection the 
medium is aspirated, the cells are washed twice with 1x PBS and 3 ml fresh M10Gi are 
added to each well. The plate is further incubated at 37°C. After 48 hours the 
transfected cells can be tested in further experiment (in this case either with Luciferase 
Assay or RNA isolation). 
7.8.1.2. Lipofectamine Transfection 
1.5 x 105 C2C12 fibroblast cells are seeded to each well of a gelled (0.1% gelatine) 
six-well plate. They are seeded in 2 ml antibiotics-free and serum reduced medium 
(M5Gi w/o antibiotics). The plate is incubated at 37°C over night. On the next day, for 
each well one Kloesch tube is prepared with 10 µl Lipofectamine 2000 reagent 
(Invitrogen) in 240 µl antibiotics- and serum-free medium. The mixture is kept at room 
temperature for 5 minutes. For each well one Kloesch tube is prepared with 8 µg of 
Plasmid – DNA dissolved in antibiotics- and serum – free medium to a total volume of 
250 µl. The Lipofectamine is then pipetted to the DNA tubes, gently mixed and kept at 
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room temperature for 20 minutes. The Lipofectamine – DNA complexes are then 
pipetted to the wells and incubated at 37°C. 6 hours or 24 hours after transfection, the 
medium is aspirated, the cells are twice washed with 1x PBS and fresh M10Gi medium 
is added. After 48 hours the transfected cells can be tested in further experiment. 
7.8.2. Transfection of CVPCs 
7.8.2.1. Lipofectamine Transfection 
1 x 105 CVPC cells are seeded on each well of a gelled 24 well plate in M15Hi 
medium. The plate is incubated at 37°C over night. On the next day, the medium is 
aspirated, the cells are washed with 1x PBS and 500 µl antibiotics-free medium 
(DMEM + 15% HyClone Serum + 1% Glutamine) are added to each well 2 hours 
before transfection. 1 µg DNA is mixed in 50 µl of DMEM + 1% Glutamine, 1 µl 
Lipofectamine 2000 is soluted in 50 µl DMEM + 1% Glutamine. The solution is kept 
at room temperature for 5 minutes. The DNA is pipetted to the Lipofectamine solution 
and kept at room temperature for 20 minutes. 100 µl are pipetted to each well and the 
plate is incubated at 37°C for 3 hours. Then the medium is aspirated and 2 ml (or less – 
at least 750 µl) M15Hi are added. After 48 hours the transfected cells can be tested in 
further experiment. 
 
7.9. Luciferase Assay 
7.9.1. Luciferase Assay of transfected Fibroblasts 
For the Luciferase Assay, the Promega Dual-Luciferase Reporter Assay System Kit is 
used. 
48 hours after transfection the medium is aspirated from the 6 well plate and the cells 
are washed twice with cold 1x PBS. 1 ml 1x Passive Lysis Buffer is added to each well 
and the plate is incubated at room temperature for 40 minutes. The cells are 
resuspended and transferred into Kloesch tubes. 50 µl of the cell suspension are 
pipetted into a 96 well Luciferase plate. For the Luciferase machine (Berthold LB960) 
LARII (for Firefly Luciferase values) and Stop&Glo solution (Stop&Glo 
Buffer:Stop&Glo Reagent 50:1, for Renilla Luciferase values) are prepared. The 
Firefly and Renilla Luciferase activity are measured (Fig. 53). 
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7.9.2. Luciferase Assay of transfected Cardiovascular Progenitor Cells 
For the Luciferase Assay, the Promega Dual-Luciferase Reporter Assay System Kit is 
used. 
48 hours after the transfection the medium is aspirated, the cells are washed with 1x 
PBS, and 200 µl 1x Passive Lysis Buffer are added to each well. The plate is incubated 
for 60 minutes at 37°C or room temperature. The cells are resuspended and transferred 
into Kloesch tubes, the wells are washed with 100 µl 1x Passive Lysis Buffer (1x 
PLB), and are diluted 1:10 in 1x PLB. For the Luciferase machine (Berthold LB960) 
LARII (for Firefly Luciferase values) and Stop&Glo solution (Stop&Glo 
Buffer:Stop&Glo Reagent 50:1, for Renilla Luciferase values) are prepared. (about 
100 µl per sample). 20 µl of the lysate are pipetted into a Luciferase plate and 
Luciferase activity is measured (Fig. 53). 
 
 
 
 
 
 
7.10. Homologue Recombination of cardiovascular progenitor cells 
The pCsx-EGFP-PP-DT plasmid was cut with Sal I enzyme to linearize. Therefore, 3 
µl Sal I (NEB #R0138S) are incubated with 30 µl NEBuffer 3 (NEB #B7003S) and 3 
µg of Plasmid DNA in a total volume of 300 µl at 37°C over night. 1.1 x 107 CVPC 
cells are pipetted into an electroporation cuvette and 260 ng linearized plasmid DNA 
are added (25 µl). The cuvette is kept at room temperature for five minutes and 
afterwards cells are electroporated at 230 V and 500 µF in a BioRad electroporation 
machine. The content of the cuvette is put onto a 10 cm feeder plate which is then 
incubated at 37°C. The cells are fed for 7 days with medium containing puromycin (1 
µg/µl) and for 2 days with puromycin – free medium. After this time, small colonies 
could be observed with clonal cells which should contain the nkx2.5-EGFP knock in 
construct. As soon, as colonies are seen on the plate, clones are picked. Therefore, 
Fig. 53 Bioluminescent 
reactions catalyzed by 
firefly and Renilla 
luciferases (Promega). 
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feeder cells in 96 wells are prefed with M15Hi medium, and 20 µl Trypsin are put into 
empty 96 well plates. The colonies are scraped off the 10 cm plate, put into the Trypsin 
wells, incubated for 10 minutes at 37°C and are resuspended with 70 µl of the prefed 
feeder cell medium. The cells are transferred to the feeder wells and incubated at 37°C 
for five days and are then transferred to 48 well feeder plates. They are fed every day 
and when the clones reach confluence, they are transferred to a 24 well feeder plate. 
This step is passage 0. The clones are fed every day. After three days when they reache 
confluence, they are split in a 1:2 ratio, one part is further cultivated, the other one is 
frozen (passage 1).  
 
7.11. Fluorescence Activated Cell Sorting (FACS) 
Here, the extent of heart cell formation in embryoid and cardiac bodies was measured 
with FACS after staining with the fluorescent heart cell marker cardiac Troponin T. 
Embryoid and Cardiac Bodies are typsinised. The pellet is resuspended in 4% 
Paraformaldehyd in PBS and incubated at room temperature for 20 minutes. The 
solution is centrifuged for 10 minutes at 1200 rpm and the pellet is resuspended in 
PBS. The solution is again centrifuged for 10 minutes at 1200 rpm and the pellet is 
resuspended in PBS. The next centrifugation for 10 minutes at 1200 rpm is followed 
by dissolving the pellet in 0.15% Saponin in PBS to permeabilise the cells. The 
solution is centrifuged for 8 minutes at 1200 rpm. The pellet is resuspended, incubated 
at room temperature for 10 minutes with 2% BSA-PBS to block unspecific binding 
sites and then partitioned to two tubes. The tubes are then centrifuged for 5 minutes at 
1000 rpm, one pellet is dissolved in primary antibody solution (cardiac TroponinT, 
Thermo Scientific #MS-295,1:200 in 2% BSA-PBS), the other one in 2% BSA-PBS 
(as a negative control) and the tubes are incubated at 4°C for at least one hour or over 
night. The suspension is centrifuged for 8 minutes at 1200 rpm, and the pellet is 
resuspended in PBS. This wash step is repeated twice. After the last step, the cells are 
partitioned to two tubes each, and one tube each is incubated with secondary antibody 
solution (anti mouse-FITC, Jackson ImmunoResearch 1:200; #711-095-151) in order 
to get four samples. The cells are incubated at 4°C for at least one hour or over night. 
The tubes are then centrifuged for 10 minutes at 1200 rpm and the pellet is 
resuspended in PBS. This wash step is repeated twice. The pellet is then dissolved in 1 
ml PBS and the cells are analyzed on a BD FACSCalibur machine. 
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7.12. Immunofluorescence 
Indirect immunfluorescence microscopy was used to detect the extent of heart cell 
formation in embryoid and cardiac bodies by staining them with the cardiac marker 
cardiac Troponin T (cTNT). Furthermore, the cardiac bodies were stained with 
Connexin 43 to detect whether they form tight cell-cell interactions.  
Embryoid and cardiac bodies are grown on 10 cm plates either covered with cover slip, 
in order to get highly magnified and detailed pictures, or without cover slips for 
overview screens. 10 ml 4% Formaldehyd in 1x PBS are added to each plate and they 
are rotated at room temperature for 20 minutes. The plates are washed twice with 1x 
PBS and 2 ml 0.1% Saponin in 1x PBS are added. The plates are rotated for 20 
minutes to permeabilise the cells. The cells are then washed twice with 1x PBS and 5 
ml 2% BSA-PBS are added to each plate to block unspecific binding sites. The plates 
are swayed for 10 minutes. The cells are then incubated with primary antibody in 2% 
BSA-TBS (cardiac TroponinT, Thermo Scientific #MS-295,1:200; Connexin 43, 
Sigma #C6219, 1:4000) at 4°C for at least one hour. They are then washed three times 
with 1x PBS for 10 minutes. Secondary Antibody in 2% BSA-TBS is added (Dianova 
α-mouse-FITC #715-095-151, 1:200; Dianova α-rabbit-TR #711-075-152) and 
incubated for one hour at 4°C. The cells are washed 10 minutes with 1x PBS. DAPI 
(Invitrogen #D1306) is diluted 1:1000 in 1x PBS, added to the plates and swayed for 5 
minutes. The plates are washed twice with 1x PBS for 15 minutes and those without 
cover slips are observed with a Zeiss Axiovert 200M microscope. The cover slips are 
put on glass slides with 50 µl of 55°C Mowiol. After drying of the Mowiol, the cover 
slips are fixed with nail polish. The fluorescence of the cells on the slides is observed 
with a Zeiss LSM 510 confocal microscope. 
Mowiol 
 6 g   Glycerin 
 2.6 g  Mowiol 2-88 
 5%   DABCO 
 6 ml  ddH2O 
The components are mixed and incubated at room temperature for 2 hours. 12 ml 0.2 
M Tris/HCl pH 8.5 are added and the solution is heated at 50°C for 10 minutes. It is 
then centrifuged for 15 minutes at 5000 rpm and aliquots are stored at -20°C. 
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7.13. Western Blot 
7.13.1. Protein Isolation 
Cells are washed with 1x PBS and Kinexus Lysis Buffer is pipetted to the plate. The 
cells are scraped off the plate, resuspended, transferred to Kloesch tubes and stored at  
-20°C. 
Kinexus Lysis Buffer 
 20 mM  Tris pH7 
 2 mM EGTA 
 5 mM  EDTA 
 30 mM  Sodiumfluorid 
 40 mM  Glycerophosphat 
 10 mM  Pyrophosphate 
 2 mM  Sodiumorthovanadate 
 10 µM  Leupeptin 
 5 µM  PepstatinA 
 0.5%  Triton X-100 
 Proteinaseinhibitor 
 ddH2O 
7.13.2. Bradford Protein Concentration Measurement 
The concentration of the proteins is measured with Bradford measurement. 
The Bradford Dye is diluted 1:4 and 196 µl dilution are pipetted into a 96 well plate. 
Different BSA concentration samples are made, and 4 µl of each (0 mg/ml; 0.156 
mg/ml; 0.313 mg/ml; 0.63 mg/ml; 1.25 mg/ml; 2.5 mg/ml) are pipetted to the wells in 
duplicates. For the samples, 199 µl Bradford dilution and 1 µl cell lysate are mixed in 
each well in duplicates. OD595 is measured with a Labsystem Multiscan RC machine. 
The protein concentration is calculated according to the BSA standards. 
Bradford Dye  
 0.5 mg/ml  Coomassie Blue 
 25%  Methanol 
 42.5%  H3PO4 
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7.13.3. SDS Separation 
For protein separation, 12.5% SDS Polyacrylamid gels are used. Firstly, the separation 
gel is poured into a gel apparatus and it is covered with isopropanol. As soon as the gel 
is hardened, isopropanol is removed, the stacking gel is poured and a comb is put into 
the liquid gel. The hardened gel is then transferred into 1x PAGE buffer. After 
Bradford measurement, the lysates are diluted with ddH2O and 3x Sample buffer to 30 
µg protein in 24 µl per sample. The samples are boiled for 5 minutes at 95°C, 
centrifuged for 2 minutes at 13000 rpm and loaded to the gel. The gel is run firstly at 
90 V until the samples are collected and build a sharp lane which enters the separation 
gel, the proteins are then separated at 120 V. 
Stacking Gel 5% 
 0.333 ml  30% Polyacrylamide 
 0.25 ml  1 M Tris/HCl pH 6.8; 0.4% SDS 
 1.385 ml  ddH2O 
 10 µl  10% APS 
 2 µl  TEMED 
Separation Gel 12.5% 
 2.083 ml  30% Polyacrylamide 
 1.875 ml  1 M Tris/HCl pH 8.8; 0.4% SDS 
 0.948 ml  ddH2O 
 40 µl  10% APS 
 4µl  TEMED 
3x Sample Buffer 
 187.5 mM  Tris/HCl pH6.8 
 6%   SDS 
 30%  Glycerol 
 0.15 M  DTT 
 0.03%  Bromphenolblau 
10x PAGE Buffer 
 1.92 M  Glycine 
 250 mM  Tris 
 1%   SDS 
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7.13.4. Blotting 
The proteins separated on a gel are blotted onto a Nitrocellulose Membrane and then 
stained with specific primary and secondary antibodies. 
The gel is put onto five Whatman paper and one Nitrocellulose membrane and is 
covered with another five Whatman paper (everything soaked in 1x Blotting Buffer). 
The proteins are blotted at 400 mA for 60 minutes. The membrane is then stained with 
Ponceau solution to visualize protein marker bands. It is destained with ddH2O and 
blocked in 5% Milk-TBST for one hour at 4°C. Primary antibody solution in 5% Milk-
TBST or 5% BSA is added (SPARC, Santa Cruz, #sc-25574, 1:200; GFP, Cell 
Signalling #2956, 1:666) and the membrane is swayed at 4°C for at least 60 minutes. 
The blot is washed three times for 5 minutes with 0.1% TBST. HRP-conjugated 
secondary antibody solution in 5% Milk-TBST or 5% BSA is added (α-rabbit-HRP, 
Dianova, #111-035-003, 1:15000; α-mouse-HRP Pierce, #31430, 1:15000) and the 
membrane is rotated at 4°C for at least 60 minutes. The membrane is washed twice for 
5 minutes with 0.1% TBST and once with 1x TBS and is detected (Cell Signaling 20x 
LumiGLO Reagent and 20x Peroxide #7003). The film (Thermo Scientific #34089) is 
developed in an AGFA Curix60 machine. 
10x Blotting Buffer 
 0.48 M  Tris 
 0.4 M  Glycin 
 pH 9.1 
Ponceau-S 
 100 mg  Ponceau-S 
 100 ml  1% glacial acetic acid 
10x TBS 
 0.5 M  Tris 
 1.5 M  NaCl 
 pH 7.6 
0.1% TBST 
 1x TBS 
 0.1% Tween 
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7.14. Dot Blot 
Dot Blot Analysis was performed with supernatants from CVPC cultures. The DotBlot 
apparatus BIORAD-DOTTM 96 wells was used. 
A nitrocellulose membrane is wetted with 1x TBS and clamped into the apparatus. 400 
µl TBS are pipetted into each well. Different concentrations of supernatant and protein 
of interest are pipetted to the wells. The apparatus is kept on room temperature for one 
hour, then the solution is sucked through the membrane so that the proteins are 
attached to the nitrocellulose membrane. The wells are washed by sucking 200 µl 1x 
TBS through the membrane. The membrane is put out of the machine and dried for 15 
minutes. It is then blocked with 5% Milk-TBST for 30 minutes. Primary Antibody 
solution in 5% Milk-TBST is added (SPARC, Santa Cruz, #sc-25574, 1:200) and the 
membrane is incubated at 4°C for 60 minutes. It is washed three times with 0.1% 
TBST for 5 minutes. HRP-conjugated secondary antibody solution in 5% Milk-TBST 
(α-rabbit-HRP, Dianova, #111-035-003, 1:15000) is added and the membrane is 
incubated at 4°C for 60 minutes. The membrane is washed twice for 5 minutes with 
0.1% TBST and once with 1x TBS and is detected (Cell Signaling 20x LumiGLO 
Reagent and 20x Peroxide #7003). The film (Thermo Scientific #34089) is developed 
in an AGFA Curix60 machine. 
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9. Abstract 
Cardiovascular diseases account for the highest percentage of deaths worldwide. The 
heart comprises cardiac stem cells, however its regenerative potential is very limited. 
Understanding the mechanisms and identifying factors activating those dormant cells 
and making them potent to differentiate and replace injured cells would be a great 
achievement for cell based therapy.  
Here, two proteins, Desmin and SPARC, were identified as positive regulators of 
cardiomyogenesis. Desmin accelerates and enhances cardiomyocyte formation in 
embryonic stem cells by binding to the cardiac transcription factor nkx2.5 promoter. 
Embryonic stem cells however differentiate into cardiomyocytes only to a low extent. 
The successful isolation of a stable cardiovascular progenitor cell line, which 
exclusively differentiates to cardiomyocytes, smooth muscle cells, and endothelial 
cells, provides an indefinite source for studying methods and mechanisms to obtain 
highly cardiomyocytes enriched cultures. Recombinant SPARC promotes 
cardiomyogenesis by upregulating cardiac specific gene expression such as nkx2.5. 
SPARC was furthermore determined to act via modulation of Wnt signalling. Wnt and 
MAPK signalling pathways play an important role during cardiomyogenesis at 
different time points of development. To study the influence of different factors on 
Nkx2.5 expression, an nkx2.5 – EGFP – positive cardiovascular progenitor reporter 
cell line was established.  
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10. Zusammenfassung 
Herz-Kreislauf-Erkrankungen machen den größten Anteil an weltweiten Todesfällen 
aus. Das Herz besitzt zwar somatische Herzstammzellen, allerdings hat es ein nur sehr 
limitiertes regeneratives Potential. Ein großer Schritt für Stammzelltherapie als 
Heilungsmethode von Erkrankungen des Herzens wäre es, Mechanismen und Faktoren 
herauszufinden, die Herzstammzellen aktivieren und sie dadurch dazu zu bringen, 
verletztes und totes Herzgewebe zu ersetzen. 
In dieser Arbeit werden zwei Proteine, Desmin und SPARC, als positive Regulatoren 
der Herzzellentwicklung beschrieben. Desmin beschleunigt und verstärkt die Bildung 
von Herzzellen in embryonalen Stammzellen indem es an die Promoterregion des 
frühen Herzzellmarkers nkx2.5 bindet. Embryonale Stammzellen entwickeln sich 
allerdings nur zu einem geringen Ausmaß zu Herzzellen, viele andere Zelltypen 
entstehen während der Differenzierung. Daher brachte die Isolierung von stabilen 
kardiovaskulären Vorläuferzelllinien eine unerschöpfliche Quelle von immer 
gleichbleibenden Zellen, die ausschließlich zu Kardiomyocyten, glatten 
Muskulaturzellen und Endothelzellen differenzieren. Diese machen es möglich, 
Methoden und Mechanismen herauszufinden, mit denen man Kulturen bekommt, die 
stark mit Kardiomyocyten angereichert sind. Rekombinantes SPARC fördert die 
Herzzellentwicklung indem es herzzellspezifische Gene hinaufreguliert. SPARC wirkt 
indem es in den Wnt Signaltransduktionsweg eingreift. Der Wnt und MAPK 
Signaltransduktionsweg spielen zu verschiedenen Zeitpunkten in der 
Herzzellentwicklung eine wichtige Rolle. Um die Auwirkung verschiedener Faktoren 
auf die Nkx2.5 Expression zu testen wurde weiters eine nkx2.5 – EGFP – positive 
Herzvorläuferzelllinie hergestellt. 
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